Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2019 | Apr. 23, 2019 | |
Document and Entity Information | ||
Entity Registrant Name | Edwards Lifesciences Corp | |
Entity Central Index Key | 0001099800 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Large Accelerated Filer | |
Entity Emerging Growth Company | false | |
Entity Small Business | false | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Entity Common Stock, Shares Outstanding | 208,501,603 |
CONSOLIDATED CONDENSED BALANCE
CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Current assets | ||
Cash and cash equivalents | $ 709.2 | $ 714.1 |
Short-term investments (Note 6) | 253.8 | 242.4 |
Accounts and other receivables, net of allowances of $8.6 and $8.9, respectively | 578 | 537.3 |
Inventories (Note 2) | 630.9 | 607 |
Prepaid expenses | 55.4 | 54.3 |
Other current assets | 141.5 | 131.8 |
Total current assets | 2,368.8 | 2,286.9 |
Long-term investments (Note 6) | 453.7 | 506.3 |
Property, plant, and equipment, net | 892.2 | 867.5 |
Operating lease right-of-use assets (Note 4) | 69.9 | |
Goodwill | 1,103.4 | 1,112.2 |
Other intangible assets, net | 341.3 | 343.2 |
Deferred income taxes | 164.5 | 174 |
Other assets | 75.5 | 33.6 |
Total assets | 5,469.3 | 5,323.7 |
Current liabilities | ||
Accounts payable and accrued liabilities (Note 2) | 623.9 | 876.6 |
Operating lease liabilities (Note 4) | 22.6 | |
Total current liabilities | 646.5 | 876.6 |
Long-term debt | 593.9 | 593.8 |
Contingent consideration liabilities (Note 8) | 185.3 | 178.6 |
Taxes payable | 259.4 | 259.4 |
Operating lease liabilities (Note 4) | 49.7 | |
Uncertain tax positions | 130.3 | 124.9 |
Other long-term liabilities | 156.7 | 150 |
Commitments and contingencies (Note 11) | ||
Stockholders' equity | ||
Preferred stock, $.01 par value, authorized 50.0 shares, no shares outstanding | 0 | 0 |
Common stock, $1.00 par value, 350.0 shares authorized, 216.0 and 215.2 shares issued, and 208.4 and 207.7 shares outstanding, respectively | 216 | 215.2 |
Additional paid-in capital | 1,449.4 | 1,384.4 |
Retained earnings | 2,944.4 | 2,694.7 |
Accumulated other comprehensive loss (Note 12) | (141.2) | (138.5) |
Treasury stock, at cost, 7.6 and 7.5 shares, respectively | (1,021.1) | (1,015.4) |
Total stockholders' equity | 3,447.5 | 3,140.4 |
Total liabilities and stockholders' equity | $ 5,469.3 | $ 5,323.7 |
CONSOLIDATED CONDENSED STATEMEN
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Income Statement [Abstract] | ||
Net sales | $ 993 | $ 894.8 |
Cost of sales | 231.8 | 233.6 |
Gross profit | 761.2 | 661.2 |
Selling, general, and administrative expenses | 280.3 | 256 |
Research and development expenses | 171.4 | 143.2 |
Intellectual property litigation expenses | 4.6 | 5.7 |
Change in fair value of contingent consideration liabilities, net (Note 8) | 6.7 | 3.8 |
Special gain (Note 5) | 24 | 0 |
Operating income | 274.2 | 252.5 |
Interest income, net | (2) | (0.8) |
Special gain (Note 5) | 0 | (7.1) |
Other income, net | (1.8) | (3.1) |
Income before provision for income taxes | 278 | 263.5 |
Provision for income taxes | 28.3 | 56.9 |
Net income | $ 249.7 | $ 206.6 |
Earnings per share: | ||
Basic (in dollars per share) | $ 1.20 | $ 0.98 |
Diluted (in dollars per share) | $ 1.18 | $ 0.96 |
Weighted-average number of common shares outstanding: | ||
Basic (in shares) | 207.9 | 210.2 |
Diluted (in shares) | 212.2 | 215.1 |
CONSOLIDATED CONDENSED BALANC_2
CONSOLIDATED CONDENSED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Statement of Financial Position [Abstract] | ||
Allowance for doubtful accounts | $ 8.6 | $ 8.9 |
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized (in shares) | 50,000,000 | 50,000,000 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 1 | $ 1 |
Common stock, shares authorized (in shares) | 350,000,000 | 350,000,000 |
Common stock, shares issued (in shares) | 216,000,000 | 215,200,000 |
Common stock, shares outstanding (in shares) | 208,400,000 | 207,700,000 |
Treasury stock (in shares) | 7,600,000 | 7,500,000 |
CONSOLIDATED CONDENSED STATEM_2
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Statement of Comprehensive Income [Abstract] | ||
Net income | $ 249.7 | $ 206.6 |
Other comprehensive income (loss), net of tax (Note 12): | ||
Foreign currency translation adjustments | (13.1) | 33.3 |
Unrealized gain (loss) on cash flow hedges | 7.2 | (9.7) |
Defined benefit pension plans | (0.1) | 0.3 |
Unrealized gain (loss) on available-for-sale investments | 3.3 | (6.1) |
Reclassification of net realized investment loss to earnings | 0 | 1.4 |
Other comprehensive (loss) income | (2.7) | 19.2 |
Comprehensive income | $ 247 | $ 225.8 |
CONSOLIDATED CONDENSED STATEM_3
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Cash flows from operating activities | ||
Net income | $ 249.7 | $ 206.6 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Depreciation and amortization | 20.6 | 19.1 |
Amortization of right-of-use-assets | 5.7 | |
Stock-based compensation (Note 10) | 20.8 | 18.4 |
Change in fair value of contingent consideration liabilities, net (Note 8) | 6.7 | 3.8 |
Deferred income taxes | 5.8 | (15.5) |
Purchase of intellectual property (Note 5) | 24 | 0 |
Other | (7) | 1 |
Changes in operating assets and liabilities: | ||
Accounts and other receivables, net | (45.8) | 27.4 |
Inventories | (29.4) | (3.3) |
Accounts payable and accrued liabilities | (242.2) | (115.5) |
Income taxes | (16.3) | 39.9 |
Prepaid expenses and other current assets | 2.8 | (26.4) |
Other | 6.1 | (4.2) |
Net cash provided by operating activities | 1.5 | 151.3 |
Cash flows from investing activities | ||
Capital expenditures | (42.2) | (43.2) |
Purchases of held-to-maturity investments (Note 6) | (30) | 0 |
Proceeds from held-to-maturity investments (Note 6) | 20 | 238.5 |
Proceeds from available-for-sale investments (Note 6) | 56.1 | 42.3 |
Investments in intangible assets | (16.8) | (3) |
Investments in trading securities, net | (1.9) | (3.1) |
Investments in unconsolidated affiliates, net (Note 6) | (1.3) | (1.8) |
Payment of contingent consideration | 0 | (10) |
Payment for acquisition option | (35) | 0 |
Other | 1.6 | 0.6 |
Net cash (used in) provided by investing activities | (49.5) | 220.3 |
Cash flows from financing activities | ||
Proceeds from issuance of debt, net | 3.7 | 5.1 |
Payments on debt and capital lease obligations | (4) | (5.1) |
Purchases of treasury stock | (5.7) | (2.1) |
Proceeds from stock plans | 45 | 44.8 |
Other | 5.4 | (1.8) |
Net cash provided by financing activities | 44.4 | 40.9 |
Effect of currency exchange rate changes on cash and cash equivalents | (1.3) | (3.8) |
Net (decrease) increase in cash and cash equivalents | (4.9) | 408.7 |
Cash and cash equivalents at beginning of period | 714.1 | 818.3 |
Cash and cash equivalents at end of period | $ 709.2 | $ 1,227 |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Millions, $ in Millions | Total | Common Stock | Treasury Stock | Additional Paid-in Capital | Retained Earnings | Total Accumulated Other Comprehensive Loss |
Beginning balance (in shares) at Dec. 31, 2017 | 212 | 2.3 | ||||
Beginning balance at Dec. 31, 2017 | $ 2,956.2 | $ 212 | $ (252.1) | $ 1,166.9 | $ 1,962.1 | $ (132.7) |
Increase (Decrease) in Stockholders' Equity | ||||||
Net income | 206.6 | 206.6 | ||||
Other comprehensive loss, net of tax | 19.2 | 19.2 | ||||
Common stock issued under equity plans (in shares) | 1 | |||||
Common stock issued under equity plans | 44.8 | $ 1 | 43.8 | |||
Stock-based compensation expense | 18.4 | 18.4 | ||||
Purchases of treasury stock | (2.1) | $ (2.1) | ||||
Ending balance (in shares) at Mar. 31, 2018 | 213 | 2.3 | ||||
Ending balance at Mar. 31, 2018 | 3,245.7 | $ 213 | $ (254.2) | 1,229.1 | 2,179.1 | (121.3) |
Beginning balance (in shares) at Dec. 31, 2018 | 215.2 | 7.5 | ||||
Beginning balance at Dec. 31, 2018 | 3,140.4 | $ 215.2 | $ (1,015.4) | 1,384.4 | 2,694.7 | (138.5) |
Increase (Decrease) in Stockholders' Equity | ||||||
Net income | 249.7 | 249.7 | ||||
Other comprehensive loss, net of tax | (2.7) | (2.7) | ||||
Common stock issued under equity plans (in shares) | 0.8 | |||||
Common stock issued under equity plans | 45 | $ 0.8 | 44.2 | |||
Stock-based compensation expense | 20.8 | 20.8 | ||||
Purchases of treasury stock (in shares) | 0.1 | |||||
Purchases of treasury stock | (5.7) | $ (5.7) | ||||
Ending balance (in shares) at Mar. 31, 2019 | 216 | 7.6 | ||||
Ending balance at Mar. 31, 2019 | $ 3,447.5 | $ 216 | $ (1,021.1) | $ 1,449.4 | $ 2,944.4 | $ (141.2) |
BASIS OF PRESENTATION
BASIS OF PRESENTATION | 3 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
BASIS OF PRESENTATION | BASIS OF PRESENTATION The accompanying interim consolidated condensed financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") and should be read in conjunction with the consolidated financial statements and notes included in Edwards Lifesciences Corporation's Annual Report on Form 10-K for the year ended December 31, 2018 . Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted. In the opinion of management, the interim consolidated condensed financial statements reflect all adjustments considered necessary for a fair statement of the interim periods. All such adjustments are of a normal, recurring nature. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. Certain reclassifications have been made to the prior year's consolidated condensed financial statements to conform to the current year presentation. Recently Adopted Accounting Standards In February 2016, the Financial Accounting Standards Board ("FASB") issued an amendment to the guidance on leases. The amendment improves transparency and comparability among companies by recognizing lease assets and lease liabilities on the balance sheet and by disclosing key information about leasing arrangements. The guidance was effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach was required upon adoption. Reporting entities could elect to adjust comparative periods and record the cumulative effect adjustment at the beginning of the earliest comparative period, or to not adjust comparative periods and record the cumulative effect adjustment at the effective date. The Company adopted the new guidance as of the effective date of January 1, 2019 with no adjustments to the comparative period presented in the financial statements. In addition, the Company elected the package of practical expedients permitted under the transition guidance to not reassess (1) whether any expired or existing contracts are, or contain, leases, (2) the lease classification for expired or existing leases, and (3) initial direct costs for existing leases. The Company implemented internal controls and system solutions to enable the preparation and disclosure of financial information about its leasing arrangements upon adoption. The adoption of the guidance resulted in the recognition of right-of-use ("ROU") assets and additional lease liabilities for operating leases of $58.7 million as of January 1, 2019. The guidance did not have an impact on the Company's consolidated condensed statements of operations. See Note 4 for disclosures related to the Company's leases. |
OTHER CONSOLIDATED FINANCIAL ST
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS | 3 Months Ended |
Mar. 31, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS | OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS Composition of Certain Financial Statement Captions Components of selected captions in the consolidated condensed balance sheets consisted of the following (in millions): March 31, 2019 December 31, 2018 Inventories Raw materials $ 112.3 $ 111.5 Work in process 161.2 144.8 Finished products 357.4 350.7 $ 630.9 $ 607.0 At March 31, 2019 and December 31, 2018 , $112.2 million and $106.5 million , respectively, of the Company's finished products inventories were held on consignment. March 31, 2019 December 31, 2018 Accounts payable and accrued liabilities Accounts payable $ 147.2 $ 134.0 Employee compensation and withholdings 152.7 226.1 Taxes payable (Note 14) 6.9 31.3 Property, payroll, and other taxes 42.2 39.5 Research and development accruals 55.7 48.9 Accrued rebates 72.4 80.0 Fair value of derivatives 4.0 4.4 Accrued marketing expenses 18.3 22.3 Litigation and insurance reserves 18.6 196.7 Accrued relocation costs 12.1 11.3 Accrued professional services 7.5 11.0 Accrued technology purchases 7.2 — Other accrued liabilities 79.1 71.1 $ 623.9 $ 876.6 Supplemental Cash Flow Information (in millions) Three Months Ended 2019 2018 Cash paid during the year for: Amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 6.1 $ — Non-cash investing and financing transactions: Right-of-use assets obtained in exchange for new lease liabilities $ 16.3 $ — Capital expenditures accruals $ 15.7 $ 15.8 |
REVENUE
REVENUE | 3 Months Ended |
Mar. 31, 2019 | |
Revenue from Contract with Customer [Abstract] | |
REVENUE | REVENUE The Company sells separately priced service contracts, which range from 12 months to 36 months, to owners of its hemodynamic monitors. The Company invoices the customer the total amount of consideration at the inception of the contract and recognizes revenue ratably over the term of the contract. As of March 31, 2019 and December 31, 2018 , $7.9 million and $7.6 million , respectively, of deferred revenue associated with outstanding service contracts was recorded in “ Accounts Payable and Accrued Liabilities ” and " Other Long-term Liabilities. " During the three months ended March 31, 2019 , the Company recognized as revenue $1.1 million that was included in the balance of deferred revenue as of December 31, 2018 . |
LEASES LEASES
LEASES LEASES | 3 Months Ended |
Mar. 31, 2019 | |
Leases [Abstract] | |
LEASES | LEASES The Company determines whether a contract is, or contains, a lease at inception. ROU assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred, and exclude any lease incentives received. The Company determines the lease term as the noncancellable period of the lease, and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Certain of the Company’s leases include variable lease payments that are based on costs incurred or actual usage, or adjusted periodically based on an index or a rate. The Company’s leases do not contain any residual value guarantees. The Company accounts for the lease and non-lease components as a single lease component for all of its leases except vehicle leases, for which the lease and non-lease components are accounted for separately. Operating leases are included in “ Operating Lease Right-of-Use Assets ” and “ Operating Lease Liabilities ” on the Company’s consolidated condensed balance sheets. The Company leases certain office space, manufacturing facilities, land, apartments, warehouses, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 22 years , some of which include options to extend or terminate the leases. Operating lease costs for the three months ended March 31, 2019 were $6.3 million . Short-term and variable lease costs were not material for the three months ended March 31, 2019 . Supplemental balance sheet information related to operating leases was as follows (in millions, except lease term and discount rate): March 31, Operating lease ROU assets $ 69.9 Operating lease liabilities, current portion 22.6 Operating lease liabilities, long-term portion 49.7 Total operating lease liabilities $ 72.3 Maturities of operating lease liabilities at March 31, 2019 were as follows (in millions): 2019 $ 18.8 2020 21.1 2021 13.9 2022 9.5 2023 6.9 Thereafter 8.2 Total lease payments $ 78.4 Less: imputed interest (6.1 ) Total lease liabilities $ 72.3 Weighted-average remaining lease term (in years) 4.5 Weighted-average discount rate 3.0 % As of March 31, 2019 , the Company had additional operating lease commitments of $12.5 million for office space that have not yet commenced. These leases will commence during 2019 with lease terms of 1 year to 10 years. Disclosures related to periods prior to adopting the new lease guidance Certain facilities and equipment are leased under operating leases expiring at various dates. Most of the operating leases contain renewal options. Total expense for all operating leases was $27.0 million , $27.3 million , and $22.9 million for the years 2018 , 2017 , and 2016 , respectively. Future minimum lease payments (including interest) under non-cancelable operating leases at December 31, 2018 were as follows (in millions): Operating 2019 $ 25.6 2020 21.5 2021 13.5 2022 9.9 2023 6.4 Thereafter 14.3 Total obligations and commitments $ 91.2 |
SPECIAL CHARGE (GAIN)
SPECIAL CHARGE (GAIN) | 3 Months Ended |
Mar. 31, 2019 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
SPECIAL CHARGE (GAIN) | SPECIAL CHARGE (GAIN) In March 2019, the Company recorded a $24.0 million charge related to the acquisition of early-stage transcatheter intellectual property and associated clinical and regulatory experience. In March 2018, the Company recorded a $7.1 million gain related to the curtailment of its defined benefit plan in Switzerland resulting from the closure of its manufacturing plant. |
INVESTMENTS
INVESTMENTS | 3 Months Ended |
Mar. 31, 2019 | |
Investments, Debt and Equity Securities [Abstract] | |
INVESTMENTS | INVESTMENTS Debt Securities Investments in debt securities at the end of each period were as follows (in millions): March 31, 2019 December 31, 2018 Held-to-maturity Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Bank time deposits $ 30.0 $ — $ — $ 30.0 $ 20.0 $ — $ — $ 20.0 Available-for-sale Commercial paper $ 36.0 $ — $ — $ 36.0 $ 56.7 $ — $ — $ 56.7 U.S. government and agency securities 79.7 0.2 (0.4 ) 79.5 79.7 0.2 (0.7 ) 79.2 Foreign government bonds 1.7 — — 1.7 1.7 — — 1.7 Asset-backed securities 102.2 0.3 (0.3 ) 102.2 110.6 0.1 (0.5 ) 110.2 Corporate debt securities 432.2 1.0 (1.5 ) 431.7 459.8 0.1 (4.3 ) 455.6 Municipal securities 2.8 — — 2.8 2.8 — — 2.8 Total $ 654.6 $ 1.5 $ (2.2 ) $ 653.9 $ 711.3 $ 0.4 $ (5.5 ) $ 706.2 The cost and fair value of investments in debt securities, by contractual maturity, as of March 31, 2019 were as follows: Held-to-Maturity Available-for-Sale Cost Fair Value Cost Fair Value (in millions) Due in 1 year or less $ 30.0 $ 30.0 $ 224.5 $ 223.8 Due after 1 year through 5 years — — 340.9 340.9 Instruments not due at a single maturity date — — 89.2 89.2 $ 30.0 $ 30.0 $ 654.6 $ 653.9 Actual maturities may differ from the contractual maturities due to call or prepayment rights. The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of March 31, 2019 and December 31, 2018 , aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in millions): March 31, 2019 Less than 12 Months 12 Months or Greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses U.S. government and agency securities $ — $ — $ 56.7 $ (0.4 ) $ 56.7 $ (0.4 ) Asset-backed securities — — 53.7 (0.3 ) 53.7 (0.3 ) Corporate debt securities 56.1 (0.2 ) 189.1 (1.3 ) 245.2 (1.5 ) $ 56.1 $ (0.2 ) $ 299.5 $ (2.0 ) $ 355.6 $ (2.2 ) December 31, 2018 Less than 12 Months 12 Months or Greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses U.S. government and agency securities $ 0.7 $ (0.1 ) $ 56.5 $ (0.6 ) $ 57.2 $ (0.7 ) Asset-backed securities 4.0 0.1 61.3 (0.6 ) 65.3 (0.5 ) Corporate debt securities 177.4 (1.1 ) 203.7 (3.2 ) 381.1 (4.3 ) $ 182.1 $ (1.1 ) $ 321.5 $ (4.4 ) $ 503.6 $ (5.5 ) Investments in Unconsolidated Affiliates The Company has a number of equity investments in privately and publicly held companies. Investments in these unconsolidated affiliates are recorded in " Long-term Investments " on the consolidated condensed balance sheets, and are as follows: March 31, December 31, (in millions) Equity method investments Cost $ 10.3 $ 9.1 Equity in losses (4.8 ) (4.7 ) Carrying value of equity method investments 5.5 4.4 Equity securities Carrying value of non-marketable equity securities 18.1 18.1 Total investments in unconsolidated affiliates $ 23.6 $ 22.5 Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values, and are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. The Company did not record any upward or downward adjustments during the three months ended March 31, 2019 . As of March 31, 2019 , the Company had recorded accumulated upward adjustments of $1.7 million based on observable price changes, and accumulated downward adjustments of $1.9 million due to impairment and observable price changes. During the three months ended March 31, 2019 , the gross realized gains or losses from sales of available-for-sale investments were not material. |
ACQUISITION
ACQUISITION | 3 Months Ended |
Mar. 31, 2019 | |
Business Combinations [Abstract] | |
ACQUISITION | ACQUISITION On February 11, 2019, the Company entered into an agreement and plan of merger to acquire CAS Medical Systems, Inc. ("CASMED") for an aggregate cash purchase price of $2.45 per share of common stock, or an equity value of approximately $100 million . The transaction closed on April 18, 2019. CASMED is a medical technology company dedicated to non-invasive monitoring of tissue oxygenation in the brain. The Company plans to integrate the acquired technology platform into its hemodynamic monitoring platform. The acquisition will be accounted for as a business combination, and is expected to consist primarily of intangible assets. |
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS | 3 Months Ended |
Mar. 31, 2019 | |
Fair Value Disclosures [Abstract] | |
FAIR VALUE MEASUREMENTS | FAIR VALUE MEASUREMENTS The consolidated condensed financial statements include financial instruments for which the fair market value of such instruments may differ from amounts reflected on a historical cost basis. Financial instruments of the Company consist of cash deposits, accounts and other receivables, investments, accounts payable, certain accrued liabilities, and borrowings under a revolving credit agreement. These financial instruments are held at cost, which generally approximates fair value due to their short-term nature. Financial instruments also include notes payable. As of March 31, 2019 , the fair value of the notes payable, based on Level 2 inputs, was $630.1 million . Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The Company prioritizes the inputs used to determine fair values in one of the following three categories: Level 1—Quoted market prices in active markets for identical assets or liabilities. Level 2—Inputs, other than quoted prices in active markets, that are observable, either directly or indirectly. Level 3—Unobservable inputs that are not corroborated by market data. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table summarizes the Company's financial instruments which are measured at fair value on a recurring basis (in millions): March 31, 2019 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 7.0 $ — $ — $ 7.0 Available-for-sale investments: Corporate debt securities — 431.7 — 431.7 Asset-backed securities — 102.2 — 102.2 U.S. government and agency securities 19.7 59.8 — 79.5 Foreign government bonds — 1.7 — 1.7 Commercial paper — 36.0 — 36.0 Municipal securities — 2.8 — 2.8 Investments held for deferred compensation plans 76.0 — — 76.0 Derivatives — 37.9 — 37.9 $ 102.7 $ 672.1 $ — $ 774.8 Liabilities Derivatives $ — $ 4.0 $ — $ 4.0 Deferred compensation plans 76.1 — — 76.1 Contingent consideration liabilities — — 185.3 185.3 $ 76.1 $ 4.0 $ 185.3 $ 265.4 December 31, 2018 Assets Cash equivalents $ — $ 11.8 $ — $ 11.8 Available-for-sale investments: Corporate debt securities — 455.6 — 455.6 Asset-backed securities — 110.2 — 110.2 U.S. government and agency securities 19.6 59.6 — 79.2 Foreign government bonds — 1.7 — 1.7 Commercial paper — 56.7 — 56.7 Municipal securities — 2.8 — 2.8 Investments held for deferred compensation plans 67.6 — — 67.6 Derivatives — 29.9 — 29.9 $ 87.2 $ 728.3 $ — $ 815.5 Liabilities Derivatives $ — $ 5.2 $ — $ 5.2 Deferred compensation plans 68.5 — — 68.5 Contingent consideration liabilities — 178.6 178.6 $ 68.5 $ 5.2 $ 178.6 $ 252.3 The following table summarizes the changes in fair value of the contingent consideration liabilities for the three months ended March 31, 2019 (in millions): Balance at December 31, 2018 $ 178.6 Changes in fair value 6.7 Balance at March 31, 2019 $ 185.3 Cash Equivalents and Available-for-sale Investments The Company estimates the fair values of its money market funds based on quoted prices in active markets for identical assets. The Company estimates the fair values of its time deposits, commercial paper, U.S. and foreign government and agency securities, municipal securities, asset-backed securities, and corporate debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades and broker-dealer quotes on the same or similar securities, benchmark yields, credit spreads, prepayment and default projections based on historical data, and other observable inputs. The Company independently reviews and validates the pricing received from the third-party pricing service by comparing the prices to prices reported by a secondary pricing source. The Company’s validation procedures have not resulted in an adjustment to the pricing received from the pricing service. Deferred Compensation Plans The Company holds investments in trading securities related to its deferred compensation plans. The investments are in a variety of stock and bond mutual funds. The fair values of these investments and the corresponding liabilities are based on quoted market prices. Derivative Instruments The Company uses derivative financial instruments in the form of foreign currency forward exchange contracts and cross currency swap contracts to manage foreign currency exposures. All derivatives contracts are recognized on the balance sheet at their fair value. The fair value of the derivative financial instruments was estimated based on quoted market foreign exchange rates and market discount rates. Judgment was employed in interpreting market data to develop estimates of fair value; accordingly, the estimates presented herein are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The use of different market assumptions or valuation methodologies could have a material effect on the estimated fair value amounts. Contingent Consideration Liabilities Certain of the Company's acquisitions involve contingent consideration arrangements. Payment of additional consideration is contingent upon the acquired company reaching certain performance milestones, such as attaining specified revenue levels or obtaining regulatory approvals. These contingent consideration liabilities are measured at estimated fair value using either a probability weighted discounted cash flow analysis or a Monte Carlo simulation model, both of which consider significant unobservable inputs. These inputs include (1) the discount rate used to present value the projected cash flows (ranging from 2.4% to 3.4% ), (2) the probability of milestone achievement (ranging from 0.0% to 98.4% ), (3) the projected payment dates (ranging from 2021 to 2025), and (4) the volatility of future revenue ( 45.0% ). The use of different assumptions could have a material effect on the estimated fair value amounts. |
DERIVATIVE INSTRUMENTS AND HEDG
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES | 3 Months Ended |
Mar. 31, 2019 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES | DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES The Company uses derivative financial instruments to manage interest rate and foreign currency risks, as summarized below. It is the Company's policy not to enter into derivative financial instruments for speculative purposes. Notional amounts are stated in United States dollar equivalents at spot exchange rates at the respective dates. Notional Amount March 31, 2019 December 31, 2018 (in millions) Foreign currency forward exchange contracts $ 1,326.1 $ 1,378.2 Cross currency swap contracts 300.0 300.0 Derivative financial instruments involve credit risk in the event the counterparty should default. It is the Company's policy to execute such instruments with global financial institutions that the Company believes to be creditworthy. The Company diversifies its derivative financial instruments among counterparties to minimize exposure to any one of these entities. The Company also uses International Swap Dealers Association master-netting agreements. The master-netting agreements provide for the net settlement of all contracts through a single payment in a single currency in the event of default, as defined by the agreements. The Company uses foreign currency forward exchange contracts, cross currency swap contracts, and foreign currency denominated debt to manage its exposure to changes in currency exchange rates from (a) future cash flows associated with intercompany transactions and certain local currency expenses expected to occur within the next 13 months (designated as cash flow hedges), (b) its net investment in certain foreign subsidiaries (designated as net investment hedges) and (c) foreign currency denominated assets or liabilities (designated as fair value hedges). The Company also uses foreign currency forward exchange contracts that are not designated as hedging instruments to offset the transaction gains and losses associated with certain assets and liabilities denominated in currencies other than their functional currencies resulting principally from intercompany and local currency transactions. All derivative financial instruments are recognized at fair value in the consolidated condensed balance sheets. For each derivative instrument that is designated as a fair value hedge, the gain or loss on the derivative included in the assessment of hedge effectiveness is recognized immediately to earnings, and offsets the loss or gain on the underlying hedged item. The Company reports in " Accumulated Other Comprehensive Loss " the gain or loss on derivative financial instruments that are designated, and that qualify, as cash flow hedges. The Company reclassifies these gains and losses into earnings in the same line item and in the same period in which the underlying hedged transactions affect earnings. Changes in the fair value of net investment hedges are reported in " Accumulated Other Comprehensive Loss " as a part of the cumulative translation adjustment and would be reclassified into earnings if the underlying net investment is sold or substantially liquidated. The portion of the change in fair value related to components excluded from the hedge effectiveness assessment are amortized into earnings over the life of the derivative. The gains and losses on derivative financial instruments for which the Company does not elect hedge accounting treatment are recognized in the consolidated statements of operations in each period based upon the change in the fair value of the derivative financial instrument. Cash flows from net investment hedges are reported as investing activities in the consolidated statements of cash flows, and cash flows from all other derivative financial instruments are reported as operating activities. The following table presents the location and fair value amounts of derivative instruments reported in the consolidated condensed balance sheets (in millions): Fair Value Derivatives designated as hedging instruments Balance Sheet Location March 31, 2019 December 31, 2018 Assets Foreign currency contracts Other current assets $ 30.2 $ 29.1 Foreign currency contracts Other assets $ 1.6 $ — Cross currency swap contracts Other assets $ 6.1 $ 0.8 Liabilities Foreign currency contracts Accounts payable and accrued liabilities $ 4.0 $ 4.4 Foreign currency contracts Other long-term liabilities $ — $ 0.8 The following table presents the effect of master-netting agreements and rights of offset on the consolidated condensed balance sheets (in millions): Gross Amounts Not Offset in the Consolidated Balance Sheet Gross Amounts Offset in the Consolidated Balance Sheet Net Amounts Presented in the Consolidated Balance Sheet March 31, 2019 Gross Amounts Financial Instruments Cash Collateral Received Net Amount Derivative assets Foreign currency contracts $ 31.8 $ — $ 31.8 $ (4.0 ) $ — $ 27.8 Cross currency swap contracts $ 6.1 $ — $ 6.1 $ — $ — $ 6.1 Derivative liabilities Foreign currency contracts $ 4.0 $ — $ 4.0 $ (4.0 ) $ — $ — December 31, 2018 Derivative assets Foreign currency contracts $ 29.1 $ — $ 29.1 $ (3.6 ) $ — $ 25.5 Cross currency swap contracts $ 0.8 $ — $ 0.8 $ — $ — $ 0.8 Derivative liabilities Foreign currency contracts $ 5.2 $ — $ 5.2 $ (3.6 ) $ — $ 1.6 The following tables present the effect of derivative and non-derivative hedging instruments on the consolidated condensed statements of operations and consolidated condensed statements of comprehensive income (in millions): Amount of Gain or (Loss) Recognized in OCI on Derivative Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income Three Months Ended Location of Gain or (Loss) Reclassified from Accumulated OCI into Income Three Months Ended 2019 2018 2019 2018 Cash flow hedges Foreign currency contracts $ 12.9 $ (15.4 ) Cost of sales $ 7.6 $ (1.5 ) Selling, general, and administrative expenses $ 0.3 $ (1.1 ) Amount of Gain or (Loss) Recognized in OCI on Derivative Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) Three Months Ended Location of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) Three Months Ended 2019 2018 2019 2018 Net investment hedges Cross currency swap contracts $ 5.3 $ — Interest income, net $ 1.6 $ — Foreign currency denominated debt $ — $ (20.2 ) In June 2018, the Company repaid and dedesignated its €370.0 million of outstanding long-term debt which had been previously designated as a net investment hedge, and concurrently entered into cross currency swap contracts, which were designated as a net investment hedge. The cross currency swaps have an expiration date of June 15, 2028. At maturity of the cross currency swap contracts, the Company will deliver the notional amount of €257.2 million and will receive $300.0 million from the counterparties. The Company will receive semi-annual interest payments from the counterparties based on a fixed interest rate until maturity of the agreements. Amount of Gain or (Loss) Recognized in Income on Derivative Three Months Ended Location of Gain or (Loss) Recognized in Income on Derivative Fair value hedges 2019 2018 Foreign currency contracts Other income, net $ (0.9 ) $ — Amount of Gain or (Loss) Recognized in Income on Derivative Three Months Ended Location of Gain or (Loss) Recognized in Income on Derivative Derivatives not designated as hedging instruments 2019 2018 Foreign currency contracts Other income, net $ (1.5 ) $ (8.9 ) The following table presents the effect of cash flow hedge accounting on the consolidated condensed statements of operations: Location and Amount of Gain or (Loss) Recognized in Income on Cash Flow Hedging Relationships Three Months Ended March 31, 2019 Cost of sales Selling, general, and administrative expenses Interest expense (income), net Other Income, net Total amounts of income and expense line items presented in the consolidated statements of operations in which the effects of fair value or cash flow hedges are recorded $ (231.8 ) $ (280.3 ) $ 2.0 $ 1.8 The effects of fair value and cash flow hedging: Gain (loss) on fair value hedging relationships: Foreign currency contracts: Hedged items — — — 1.8 Derivatives designated as hedging instruments — — — (1.8 ) Amount excluded from effectiveness testing recognized in earnings based on an amortization approach — — — 0.9 Gain (loss) on cash flow hedging relationships: Foreign currency contracts: Amount of gain (loss) reclassified from accumulated OCI into income $ 7.6 $ 0.3 $ — $ — Location and Amount of Gain or (Loss) Recognized in Income on Cash Flow Hedging Relationships Three Months Ended March 31, 2018 Cost of sales Selling, general, and administrative expenses Total amounts of income and expense line items presented in the consolidated statements of operations in which the effects of fair value or cash flow hedges are recorded $ (233.6 ) $ (256.0 ) The effects of fair value and cash flow hedging: Gain (loss) on cash flow hedging relationships: Foreign currency contracts: Amount of gain (loss) reclassified from accumulated OCI into income $ (1.5 ) $ (1.1 ) The Company expects that during the next twelve months it will reclassify to earnings a $12.3 million gain currently recorded in " Accumulated Other Comprehensive Loss ." |
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION | 3 Months Ended |
Mar. 31, 2019 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
STOCK-BASED COMPENSATION | STOCK-BASED COMPENSATION Stock-based compensation expense related to awards issued under the Company's incentive compensation plans for the three months ended March 31, 2019 and 2018 was as follows (in millions): Three Months Ended 2019 2018 Cost of sales $ 4.0 $ 3.0 Selling, general, and administrative expenses 12.7 11.8 Research and development expenses 4.1 3.6 Total stock-based compensation expense $ 20.8 $ 18.4 At March 31, 2019 , the total remaining compensation cost related to nonvested stock options, restricted stock units, market-based restricted stock units, performance-based restricted stock units, and employee stock purchase plan ("ESPP") subscription awards amounted to $110.4 million , which will be amortized on a straight-line basis over the weighted-average remaining requisite service period of 29 months . Fair Value Disclosures The following table includes the weighted-average grant-date fair values of stock options granted during the periods indicated and the related weighted-average assumptions used in the Black-Scholes option pricing model: Option Awards Three Months Ended 2019 2018 Average risk-free interest rate 2.5 % 2.6 % Expected dividend yield None None Expected volatility 29.2 % 33.2 % Expected term (years) 5.2 4.7 Fair value, per option $ 54.03 $ 43.45 The following table includes the weighted-average grant-date fair values for ESPP subscriptions granted during the periods indicated and the related weighted-average assumptions used in the Black-Scholes option pricing model: ESPP Three Months Ended 2019 2018 Average risk-free interest rate 2.4 % 1.5 % Expected dividend yield None None Expected volatility 32.6 % 32.6 % Expected term (years) 0.6 0.6 Fair value, per share $ 48.83 $ 35.07 |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 3 Months Ended |
Mar. 31, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIES On January 28, 2019, Abbott Cardiovascular Systems, Inc. and Evalve, Inc., both subsidiaries of Abbott Laboratories (collectively "Abbott") filed a lawsuit against Edwards Lifesciences Corporation and Edwards Lifesciences, LLC, (“Edwards”) in the Federal District Court in the District of Delaware alleging that the Edwards PASCAL heart valve repair system infringes certain claims of Abbott’s U.S. Patent Nos. 7,288,097, 6,752,813, 7,563,267, 7,736,388, and 8,057,493, seeking unspecified monetary damages and preliminary and permanent injunctive relief. Thereafter, Abbott sought a preliminary injunction and a temporary restraining order. The court denied Abbott’s request for a temporary restraining order on March 5, 2019 and heard Abbott’s request for a preliminary injunction on April 15, 2019. On January 28, 2019, Abbott and its Abbott Medical UK Limited subsidiary (inclusively and collectively also "Abbott”) filed a lawsuit in the United Kingdom in the High Court of Justice, Chancery Division, Patents Court, against Edwards Lifesciences Limited, alleging that the Edwards PASCAL heart valve repair system infringes certain claims of Abbott’s UK national patents arising from EP 1 624 810 B1 (the " ‘810 patent") and EP 1 408 850 B1 (the “ ‘850 patent”). Abbott has requested a preliminary injunction and the High Court is scheduled to hear that request on or before May 3, 2019. The trial is scheduled to begin on or before December 11, 2019. On January 28, 2019, Abbott Medical GmbH (inclusively and collectively also "Abbott”) filed a lawsuit in the District Court in Düsseldorf, Germany against Edwards Lifesciences Corporation and its German subsidiary, Edwards Lifesciences Services GmbH, alleging that the Edwards PASCAL heart valve repair system infringes certain claims of Abbott’s German national patents arising from the ‘810 and ‘850 European patents. The District Court has scheduled trial for July 14, 2020. On March 15, 2019, Edwards filed a lawsuit in the German Patent Court in Munich, Germany, alleging that Abbott’s ‘850 patent is invalid. The Abbott ‘810 patent is already subject to opposition proceedings at the European Patent Office. On January 28, 2019, Abbott and Abbott Medical AG (inclusively and collectively also "Abbott”) filed a lawsuit in the Federal Patent Court in St. Gallen, Switzerland against Edwards Lifesciences AG, Edwards Lifesciences Technology Sàrl, Edwards Lifesciences IPRM AG, and Mitral Valve Technologies Sàrl, alleging that the Edwards PASCAL heart valve repair system infringes Abbott’s Swiss national patents arising from the same European patents. Abbott has requested a preliminary injunction. On January 28, 2019, Abbott Cardiovascular System Inc., Abbott Medical Italia S.p.A and Evalve Inc. (inclusively and collectively also "Abbott”) filed a lawsuit in the Civil Court of Milan, Italy against Edwards Lifesciences Corporation, Edwards Lifesciences LLC, and Edwards Lifesciences Italia SpA, alleging that the Edwards PASCAL heart valve repair system infringes Abbott’s Italian national patent arising from its ‘850 European patent. The lawsuit seeks a preliminary injunction. The Company intends to defend itself vigorously in these matters. On February 22, 2019, Edwards Lifesciences Corporation and Edwards Lifesciences, LLC filed a lawsuit against Abbott Cardiovascular Systems, Inc. in the Federal District Court in the Central District of California alleging that Abbott’s MITRACLIP device infringes Edwards’ U.S. Patent Nos. 6,719,767, 7,011,669, and 8,062,313 related to heart implant technology and seeking unspecified monetary damages. A trial date has not yet been scheduled. In addition, Edwards Lifesciences is or may be a party to, or may otherwise be responsible for, pending or threatened lawsuits related primarily to products and services currently or formerly manufactured or performed, as applicable, by Edwards Lifesciences (the "Other Lawsuits"). The Other Lawsuits raise difficult and complex factual and legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit is brought, and differences in applicable law. Management does not believe that any charge relating to the Other Lawsuits would have a material adverse effect on Edwards Lifesciences’ overall financial position, results of operations, or liquidity. However, the resolution of one or more of the Other Lawsuits in any reporting period, could have a material adverse impact on Edwards Lifesciences' net income or cash flows for that period. The Company is not able to estimate the amount or range of any loss for legal contingencies for which there is no reserve or additional loss for matters already reserved. Edwards Lifesciences is subject to various environmental laws and regulations both within and outside of the United States. The operations of Edwards Lifesciences, like those of other medical device companies, involve the use of substances regulated under environmental laws, primarily in manufacturing and sterilization processes. While it is difficult to quantify the potential impact of continuing compliance with environmental protection laws, management believes that such compliance will not have a material impact on Edwards Lifesciences' financial position, results of operations, or liquidity. |
ACCUMULATED OTHER COMPREHENSIVE
ACCUMULATED OTHER COMPREHENSIVE LOSS | 3 Months Ended |
Mar. 31, 2019 | |
Equity [Abstract] | |
ACCUMULATED OTHER COMPREHENSIVE LOSS | ACCUMULATED OTHER COMPREHENSIVE LOSS The following table is a summary of activity for each component of " Accumulated Other Comprehensive Loss " for the three months ended March 31, 2019 (in millions): Foreign Currency Translation Adjustments Unrealized Gain on Cash Flow Hedges Unrealized Loss on Available-for-sale Investments Unrealized Pension Costs Total Accumulated Other Comprehensive Loss December 31, 2018 $ (143.6 ) $ 23.6 $ (5.0 ) $ (13.5 ) $ (138.5 ) Other comprehensive (loss) gain before reclassifications (10.2 ) 15.6 4.4 (0.1 ) 9.7 Amounts reclassified from accumulated other comprehensive loss (1.6 ) (7.0 ) — — (8.6 ) Deferred income tax expense (1.3 ) (1.4 ) (1.1 ) — (3.8 ) March 31, 2019 $ (156.7 ) $ 30.8 $ (1.7 ) $ (13.6 ) $ (141.2 ) The following table provides information about amounts reclassified from " Accumulated Other Comprehensive Loss " (in millions): Three Months Ended Affected Line on Consolidated Condensed Statements of Operations Details about Accumulated Other Comprehensive Loss Components 2019 2018 Foreign currency translation adjustments $ 1.6 $ — Other income, net (0.4 ) — Provision for income taxes $ 1.2 $ — Net of tax Gain on hedges $ 7.6 $ (1.5 ) Cost of sales 0.3 (1.1 ) Selling, general, and administrative expenses (0.9 ) — Other income, net 7.0 (2.6 ) Total before tax (2.0 ) 0.7 Provision for income taxes $ 5.0 $ (1.9 ) Net of tax Loss on available-for-sale investments $ — $ (1.4 ) Other income, net — 0.1 Provision for income taxes $ — $ (1.3 ) Net of tax Unrealized pension costs $ — $ (0.6 ) Other income, net — 0.1 Provision for income taxes $ — $ (0.5 ) |
EARNINGS PER SHARE
EARNINGS PER SHARE | 3 Months Ended |
Mar. 31, 2019 | |
Earnings Per Share [Abstract] | |
EARNINGS PER SHARE | EARNINGS PER SHARE Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during a period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, nonvested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive. The table below presents the computation of basic and diluted earnings per share (in millions, except for per share information): Three Months Ended 2019 2018 Basic: Net income $ 249.7 $ 206.6 Weighted-average shares outstanding 207.9 210.2 Basic earnings per share $ 1.20 $ 0.98 Diluted: Net income $ 249.7 $ 206.6 Weighted-average shares outstanding 207.9 210.2 Dilutive effect of stock plans 4.3 4.9 Dilutive weighted-average shares outstanding 212.2 215.1 Diluted earnings per share $ 1.18 $ 0.96 Stock options, restricted stock units, and market-based restricted stock units to purchase 0.2 million and 1.2 million shares for the three months ended March 31, 2019 and 2018 , respectively, were outstanding, but were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive. |
INCOME TAXES
INCOME TAXES | 3 Months Ended |
Mar. 31, 2019 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | INCOME TAXES The Company's effective income tax rates were 10.2% and 21.6% for the three months ended March 31, 2019 and 2018 , respectively. The effective rate for the three months ended March 31, 2019 is lower than the federal statutory rate of 21% primarily due to the tax benefit from employee share-based compensation and foreign earnings taxed at lower rates. The effective rate for the three months ended March 31, 2018 included expense of $24.0 million related to the adjustment of the estimated provisional amounts recorded at December 31, 2017 in accordance with SEC Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act. The effective rates for the three months ended March 31, 2019 and 2018 include a tax benefit from employee share-based compensation of $19.0 million and $14.2 million , respectively. The Company strives to resolve open matters with each tax authority at the examination level and could reach agreement with a tax authority at any time. While the Company has accrued for matters it believes are more likely than not to require settlement, the final outcome with a tax authority may result in a tax liability that is more or less than that reflected in the consolidated condensed financial statements. Furthermore, the Company may later decide to challenge any assessments, if made, and may exercise its right to appeal. The uncertain tax positions are reviewed quarterly and adjusted as events occur that affect potential liabilities for additional taxes, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, negotiations between tax authorities, identification of new issues, and issuance of new legislation, regulations, or case law. As of March 31, 2019 and December 31, 2018 , the liability for income taxes associated with uncertain tax positions was $161.9 million and $150.7 million , respectively. The Company estimates that these liabilities would be reduced by $47.4 million and $42.7 million , respectively, from offsetting tax benefits associated with the correlative effects of potential transfer pricing adjustments, state income taxes, and timing adjustments. The net amounts of $114.5 million and $108.0 million , respectively, if not required, would favorably affect the Company's effective tax rate. At March 31, 2019, all material state, local, and foreign income tax matters have been concluded for years through 2008. The Internal Revenue Service ("IRS") began its examination of the 2015 and 2016 tax years during the fourth quarter of 2018 and its examination of the 2017 tax year during the first quarter of 2019. During 2018, the Company executed an Advance Pricing Agreement between the United States and Switzerland governments for tax years 2009 through 2020 covering various transfer pricing matters and the Company has updated its transfer pricing policies accordingly. Certain intercompany transactions covering tax years 2015 through 2018 were not resolved and those related tax positions remain uncertain. These transfer pricing matters may be significant to the Company's consolidated condensed financial statements. |
SEGMENT INFORMATION
SEGMENT INFORMATION | 3 Months Ended |
Mar. 31, 2019 | |
Segment Reporting [Abstract] | |
SEGMENT INFORMATION | SEGMENT INFORMATION Edwards Lifesciences conducts operations worldwide and is managed in the following geographical regions: United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company's geographic segments are reported based on the financial information provided to the Chief Operating Decision Maker (the Chief Executive Officer). The Company evaluates the performance of its geographic segments based on net sales and income before provision for income taxes ("pre-tax income"). The accounting policies of the segments are substantially the same as those described in Note 2 of the Company's consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2018 . Segment net sales and segment pre-tax income are based on internally derived standard foreign exchange rates, which may differ from year to year, and do not include inter-segment profits. Because of the interdependence of the reportable segments, the operating profit as presented may not be representative of the geographical distribution that would occur if the segments were not interdependent. Net sales by geographic area are based on the location of the customer. Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include net interest expense, global marketing expenses, corporate research and development expenses, manufacturing variances, corporate headquarters costs, special gains and charges, stock-based compensation, foreign currency hedging activities, certain litigation costs, and most of the Company's amortization expense. Although most of the Company's depreciation expense is included in segment pre-tax income, due to the Company's methodology for cost build-up, it is impractical to determine the amount of depreciation expense included in each segment, and, therefore, a portion is maintained at the corporate level. The Company neither discretely allocates assets to its operating segments, nor evaluates the operating segments using discrete asset information. The table below presents information about Edwards Lifesciences' reportable segments (in millions): Three Months Ended 2019 2018 Segment Net Sales United States $ 562.8 $ 479.5 Europe 227.3 205.3 Japan 99.2 91.1 Rest of World 96.8 91.7 Total segment net sales $ 986.1 $ 867.6 Segment Operating Income United States $ 383.3 $ 313.8 Europe 119.4 103.0 Japan 61.0 54.8 Rest of World 30.8 29.0 Total segment operating income $ 594.5 $ 500.6 The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions): Three Months Ended 2019 2018 Net Sales Reconciliation Segment net sales $ 986.1 $ 867.6 Foreign currency 6.9 27.2 Consolidated net sales $ 993.0 $ 894.8 Pre-tax Income Reconciliation Segment operating income $ 594.5 $ 500.6 Unallocated amounts: Corporate items (306.5 ) (248.1 ) Special charge (Note 5) (24.0 ) — Intellectual property litigation expenses (4.6 ) (5.7 ) Foreign currency 14.8 5.7 Consolidated operating income 274.2 252.5 Non-operating income 3.8 11.0 Consolidated pre-tax income $ 278.0 $ 263.5 Enterprise-wide Information Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements. Three Months Ended 2019 2018 Net Sales by Geographic Area United States $ 562.8 $ 479.5 Europe 234.7 230.0 Japan 98.4 92.7 Rest of World 97.1 92.6 $ 993.0 $ 894.8 Net Sales by Major Product and Service Area Transcatheter Aortic Valve Replacement $ 597.7 $ 551.1 Transcatheter Mitral and Tricuspid Therapies 4.3 0.5 Surgical Structural Heart 214.7 179.5 Critical Care 176.3 163.7 $ 993.0 $ 894.8 March 31, 2019 December 31, 2018 (in millions) Long-lived Tangible Assets by Geographic Area United States $ 727.3 $ 642.1 Europe 51.4 36.6 Japan 16.7 6.7 Rest of World 242.1 214.4 $ 1,037.5 $ 899.8 |
BASIS OF PRESENTATION (Policies
BASIS OF PRESENTATION (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Basis of Presentation | The accompanying interim consolidated condensed financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") and should be read in conjunction with the consolidated financial statements and notes included in Edwards Lifesciences Corporation's Annual Report on Form 10-K for the year ended December 31, 2018 . Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted. In the opinion of management, the interim consolidated condensed financial statements reflect all adjustments considered necessary for a fair statement of the interim periods. All such adjustments are of a normal, recurring nature. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. Certain reclassifications have been made to the prior year's consolidated condensed financial statements to conform to the current year presentation. |
Recently Adopted Accounting Standards and New Accounting Standards Not Yet Adopted | Recently Adopted Accounting Standards In February 2016, the Financial Accounting Standards Board ("FASB") issued an amendment to the guidance on leases. The amendment improves transparency and comparability among companies by recognizing lease assets and lease liabilities on the balance sheet and by disclosing key information about leasing arrangements. The guidance was effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach was required upon adoption. Reporting entities could elect to adjust comparative periods and record the cumulative effect adjustment at the beginning of the earliest comparative period, or to not adjust comparative periods and record the cumulative effect adjustment at the effective date. The Company adopted the new guidance as of the effective date of January 1, 2019 with no adjustments to the comparative period presented in the financial statements. In addition, the Company elected the package of practical expedients permitted under the transition guidance to not reassess (1) whether any expired or existing contracts are, or contain, leases, (2) the lease classification for expired or existing leases, and (3) initial direct costs for existing leases. The Company implemented internal controls and system solutions to enable the preparation and disclosure of financial information about its leasing arrangements upon adoption. The adoption of the guidance resulted in the recognition of right-of-use ("ROU") assets and additional lease liabilities for operating leases of $58.7 million as of January 1, 2019. The guidance did not have an impact on the Company's consolidated condensed statements of operations. See Note 4 for disclosures related to the Company's leases. |
Revenue Recognition | The Company sells separately priced service contracts, which range from 12 months to 36 months, to owners of its hemodynamic monitors. The Company invoices the customer the total amount of consideration at the inception of the contract and recognizes revenue ratably over the term of the contract. As of March 31, 2019 and December 31, 2018 , $7.9 million and $7.6 million , respectively, of deferred revenue associated with outstanding service contracts was recorded in “ Accounts Payable and Accrued Liabilities ” and " Other Long-term Liabilities. " During the three months ended March 31, 2019 , the Company recognized as revenue $1.1 million that was included in the balance of deferred revenue as of December 31, 2018 . |
OTHER CONSOLIDATED FINANCIAL _2
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Components of Selected Captions in the Consolidated Condensed Balance Sheets | Components of selected captions in the consolidated condensed balance sheets consisted of the following (in millions): March 31, 2019 December 31, 2018 Inventories Raw materials $ 112.3 $ 111.5 Work in process 161.2 144.8 Finished products 357.4 350.7 $ 630.9 $ 607.0 |
Schedule of Accounts Payable and Accrued Liabilities | March 31, 2019 December 31, 2018 Accounts payable and accrued liabilities Accounts payable $ 147.2 $ 134.0 Employee compensation and withholdings 152.7 226.1 Taxes payable (Note 14) 6.9 31.3 Property, payroll, and other taxes 42.2 39.5 Research and development accruals 55.7 48.9 Accrued rebates 72.4 80.0 Fair value of derivatives 4.0 4.4 Accrued marketing expenses 18.3 22.3 Litigation and insurance reserves 18.6 196.7 Accrued relocation costs 12.1 11.3 Accrued professional services 7.5 11.0 Accrued technology purchases 7.2 — Other accrued liabilities 79.1 71.1 $ 623.9 $ 876.6 |
Schedule of Cash Flow, Supplemental Disclosures | Supplemental Cash Flow Information (in millions) Three Months Ended 2019 2018 Cash paid during the year for: Amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 6.1 $ — Non-cash investing and financing transactions: Right-of-use assets obtained in exchange for new lease liabilities $ 16.3 $ — Capital expenditures accruals $ 15.7 $ 15.8 |
LEASES (Tables)
LEASES (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Leases [Abstract] | |
Assets and Liabilities of Lessee | Supplemental balance sheet information related to operating leases was as follows (in millions, except lease term and discount rate): March 31, Operating lease ROU assets $ 69.9 Operating lease liabilities, current portion 22.6 Operating lease liabilities, long-term portion 49.7 Total operating lease liabilities $ 72.3 |
Lessee, Operating Lease, Liability, Maturity | Maturities of operating lease liabilities at March 31, 2019 were as follows (in millions): 2019 $ 18.8 2020 21.1 2021 13.9 2022 9.5 2023 6.9 Thereafter 8.2 Total lease payments $ 78.4 Less: imputed interest (6.1 ) Total lease liabilities $ 72.3 Weighted-average remaining lease term (in years) 4.5 Weighted-average discount rate 3.0 % |
Schedule of Future Minimum Rental Payments for Operating Leases | Future minimum lease payments (including interest) under non-cancelable operating leases at December 31, 2018 were as follows (in millions): Operating 2019 $ 25.6 2020 21.5 2021 13.5 2022 9.9 2023 6.4 Thereafter 14.3 Total obligations and commitments $ 91.2 |
INVESTMENTS (Tables)
INVESTMENTS (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Investments, Debt and Equity Securities [Abstract] | |
Schedule of Investments in Debt Securities | Investments in debt securities at the end of each period were as follows (in millions): March 31, 2019 December 31, 2018 Held-to-maturity Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Bank time deposits $ 30.0 $ — $ — $ 30.0 $ 20.0 $ — $ — $ 20.0 Available-for-sale Commercial paper $ 36.0 $ — $ — $ 36.0 $ 56.7 $ — $ — $ 56.7 U.S. government and agency securities 79.7 0.2 (0.4 ) 79.5 79.7 0.2 (0.7 ) 79.2 Foreign government bonds 1.7 — — 1.7 1.7 — — 1.7 Asset-backed securities 102.2 0.3 (0.3 ) 102.2 110.6 0.1 (0.5 ) 110.2 Corporate debt securities 432.2 1.0 (1.5 ) 431.7 459.8 0.1 (4.3 ) 455.6 Municipal securities 2.8 — — 2.8 2.8 — — 2.8 Total $ 654.6 $ 1.5 $ (2.2 ) $ 653.9 $ 711.3 $ 0.4 $ (5.5 ) $ 706.2 |
Schedule of Cost and Fair Value of Investments in Debt Securities, By Contractual Maturity | The cost and fair value of investments in debt securities, by contractual maturity, as of March 31, 2019 were as follows: Held-to-Maturity Available-for-Sale Cost Fair Value Cost Fair Value (in millions) Due in 1 year or less $ 30.0 $ 30.0 $ 224.5 $ 223.8 Due after 1 year through 5 years — — 340.9 340.9 Instruments not due at a single maturity date — — 89.2 89.2 $ 30.0 $ 30.0 $ 654.6 $ 653.9 |
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value | The following tables present gross unrealized losses and fair values for those investments that were in an unrealized loss position as of March 31, 2019 and December 31, 2018 , aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in millions): March 31, 2019 Less than 12 Months 12 Months or Greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses U.S. government and agency securities $ — $ — $ 56.7 $ (0.4 ) $ 56.7 $ (0.4 ) Asset-backed securities — — 53.7 (0.3 ) 53.7 (0.3 ) Corporate debt securities 56.1 (0.2 ) 189.1 (1.3 ) 245.2 (1.5 ) $ 56.1 $ (0.2 ) $ 299.5 $ (2.0 ) $ 355.6 $ (2.2 ) December 31, 2018 Less than 12 Months 12 Months or Greater Total Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses Fair Value Gross Unrealized Losses U.S. government and agency securities $ 0.7 $ (0.1 ) $ 56.5 $ (0.6 ) $ 57.2 $ (0.7 ) Asset-backed securities 4.0 0.1 61.3 (0.6 ) 65.3 (0.5 ) Corporate debt securities 177.4 (1.1 ) 203.7 (3.2 ) 381.1 (4.3 ) $ 182.1 $ (1.1 ) $ 321.5 $ (4.4 ) $ 503.6 $ (5.5 ) |
Schedule of Investments in Unconsolidated Affiliates | Investments in these unconsolidated affiliates are recorded in " Long-term Investments " on the consolidated condensed balance sheets, and are as follows: March 31, December 31, (in millions) Equity method investments Cost $ 10.3 $ 9.1 Equity in losses (4.8 ) (4.7 ) Carrying value of equity method investments 5.5 4.4 Equity securities Carrying value of non-marketable equity securities 18.1 18.1 Total investments in unconsolidated affiliates $ 23.6 $ 22.5 |
FAIR VALUE MEASUREMENTS (Tables
FAIR VALUE MEASUREMENTS (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Fair Value Disclosures [Abstract] | |
Summary of Financial Instruments Measured at Fair Value on a Recurring Basis | The following table summarizes the Company's financial instruments which are measured at fair value on a recurring basis (in millions): March 31, 2019 Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 7.0 $ — $ — $ 7.0 Available-for-sale investments: Corporate debt securities — 431.7 — 431.7 Asset-backed securities — 102.2 — 102.2 U.S. government and agency securities 19.7 59.8 — 79.5 Foreign government bonds — 1.7 — 1.7 Commercial paper — 36.0 — 36.0 Municipal securities — 2.8 — 2.8 Investments held for deferred compensation plans 76.0 — — 76.0 Derivatives — 37.9 — 37.9 $ 102.7 $ 672.1 $ — $ 774.8 Liabilities Derivatives $ — $ 4.0 $ — $ 4.0 Deferred compensation plans 76.1 — — 76.1 Contingent consideration liabilities — — 185.3 185.3 $ 76.1 $ 4.0 $ 185.3 $ 265.4 December 31, 2018 Assets Cash equivalents $ — $ 11.8 $ — $ 11.8 Available-for-sale investments: Corporate debt securities — 455.6 — 455.6 Asset-backed securities — 110.2 — 110.2 U.S. government and agency securities 19.6 59.6 — 79.2 Foreign government bonds — 1.7 — 1.7 Commercial paper — 56.7 — 56.7 Municipal securities — 2.8 — 2.8 Investments held for deferred compensation plans 67.6 — — 67.6 Derivatives — 29.9 — 29.9 $ 87.2 $ 728.3 $ — $ 815.5 Liabilities Derivatives $ — $ 5.2 $ — $ 5.2 Deferred compensation plans 68.5 — — 68.5 Contingent consideration liabilities — 178.6 178.6 $ 68.5 $ 5.2 $ 178.6 $ 252.3 |
Summary of Changes in Fair Value of Contingent Consideration Obligation | The following table summarizes the changes in fair value of the contingent consideration liabilities for the three months ended March 31, 2019 (in millions): Balance at December 31, 2018 $ 178.6 Changes in fair value 6.7 Balance at March 31, 2019 $ 185.3 |
DERIVATIVE INSTRUMENTS AND HE_2
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Summary of Derivative Financial Instruments Used to Manage Currency Exchange Rate Risk and Interest Rate Risk | The Company uses derivative financial instruments to manage interest rate and foreign currency risks, as summarized below. It is the Company's policy not to enter into derivative financial instruments for speculative purposes. Notional amounts are stated in United States dollar equivalents at spot exchange rates at the respective dates. Notional Amount March 31, 2019 December 31, 2018 (in millions) Foreign currency forward exchange contracts $ 1,326.1 $ 1,378.2 Cross currency swap contracts 300.0 300.0 |
Schedule of Location and Fair Value Amounts of Derivative Instruments Reported in Consolidated Condensed Balance Sheets | The following table presents the location and fair value amounts of derivative instruments reported in the consolidated condensed balance sheets (in millions): Fair Value Derivatives designated as hedging instruments Balance Sheet Location March 31, 2019 December 31, 2018 Assets Foreign currency contracts Other current assets $ 30.2 $ 29.1 Foreign currency contracts Other assets $ 1.6 $ — Cross currency swap contracts Other assets $ 6.1 $ 0.8 Liabilities Foreign currency contracts Accounts payable and accrued liabilities $ 4.0 $ 4.4 Foreign currency contracts Other long-term liabilities $ — $ 0.8 |
Schedule of Effect of Master-Netting Agreements and Rights of Offset, Derivative Assets | The following table presents the effect of master-netting agreements and rights of offset on the consolidated condensed balance sheets (in millions): Gross Amounts Not Offset in the Consolidated Balance Sheet Gross Amounts Offset in the Consolidated Balance Sheet Net Amounts Presented in the Consolidated Balance Sheet March 31, 2019 Gross Amounts Financial Instruments Cash Collateral Received Net Amount Derivative assets Foreign currency contracts $ 31.8 $ — $ 31.8 $ (4.0 ) $ — $ 27.8 Cross currency swap contracts $ 6.1 $ — $ 6.1 $ — $ — $ 6.1 Derivative liabilities Foreign currency contracts $ 4.0 $ — $ 4.0 $ (4.0 ) $ — $ — December 31, 2018 Derivative assets Foreign currency contracts $ 29.1 $ — $ 29.1 $ (3.6 ) $ — $ 25.5 Cross currency swap contracts $ 0.8 $ — $ 0.8 $ — $ — $ 0.8 Derivative liabilities Foreign currency contracts $ 5.2 $ — $ 5.2 $ (3.6 ) $ — $ 1.6 |
Schedule of Effect of Master-Netting Agreements and Rights of Offset, Derivative Liabilities | The following table presents the effect of master-netting agreements and rights of offset on the consolidated condensed balance sheets (in millions): Gross Amounts Not Offset in the Consolidated Balance Sheet Gross Amounts Offset in the Consolidated Balance Sheet Net Amounts Presented in the Consolidated Balance Sheet March 31, 2019 Gross Amounts Financial Instruments Cash Collateral Received Net Amount Derivative assets Foreign currency contracts $ 31.8 $ — $ 31.8 $ (4.0 ) $ — $ 27.8 Cross currency swap contracts $ 6.1 $ — $ 6.1 $ — $ — $ 6.1 Derivative liabilities Foreign currency contracts $ 4.0 $ — $ 4.0 $ (4.0 ) $ — $ — December 31, 2018 Derivative assets Foreign currency contracts $ 29.1 $ — $ 29.1 $ (3.6 ) $ — $ 25.5 Cross currency swap contracts $ 0.8 $ — $ 0.8 $ — $ — $ 0.8 Derivative liabilities Foreign currency contracts $ 5.2 $ — $ 5.2 $ (3.6 ) $ — $ 1.6 |
Schedule of Effect of Derivative Instruments on Consolidated Condensed Statements of Operations and Consolidated Condensed Statements of Comprehensive Income | Amount of Gain or (Loss) Recognized in Income on Derivative Three Months Ended Location of Gain or (Loss) Recognized in Income on Derivative Fair value hedges 2019 2018 Foreign currency contracts Other income, net $ (0.9 ) $ — Amount of Gain or (Loss) Recognized in Income on Derivative Three Months Ended Location of Gain or (Loss) Recognized in Income on Derivative Derivatives not designated as hedging instruments 2019 2018 Foreign currency contracts Other income, net $ (1.5 ) $ (8.9 ) The following tables present the effect of derivative and non-derivative hedging instruments on the consolidated condensed statements of operations and consolidated condensed statements of comprehensive income (in millions): Amount of Gain or (Loss) Recognized in OCI on Derivative Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income Three Months Ended Location of Gain or (Loss) Reclassified from Accumulated OCI into Income Three Months Ended 2019 2018 2019 2018 Cash flow hedges Foreign currency contracts $ 12.9 $ (15.4 ) Cost of sales $ 7.6 $ (1.5 ) Selling, general, and administrative expenses $ 0.3 $ (1.1 ) Amount of Gain or (Loss) Recognized in OCI on Derivative Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) Three Months Ended Location of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) Three Months Ended 2019 2018 2019 2018 Net investment hedges Cross currency swap contracts $ 5.3 $ — Interest income, net $ 1.6 $ — Foreign currency denominated debt $ — $ (20.2 ) |
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) | The following table presents the effect of cash flow hedge accounting on the consolidated condensed statements of operations: Location and Amount of Gain or (Loss) Recognized in Income on Cash Flow Hedging Relationships Three Months Ended March 31, 2019 Cost of sales Selling, general, and administrative expenses Interest expense (income), net Other Income, net Total amounts of income and expense line items presented in the consolidated statements of operations in which the effects of fair value or cash flow hedges are recorded $ (231.8 ) $ (280.3 ) $ 2.0 $ 1.8 The effects of fair value and cash flow hedging: Gain (loss) on fair value hedging relationships: Foreign currency contracts: Hedged items — — — 1.8 Derivatives designated as hedging instruments — — — (1.8 ) Amount excluded from effectiveness testing recognized in earnings based on an amortization approach — — — 0.9 Gain (loss) on cash flow hedging relationships: Foreign currency contracts: Amount of gain (loss) reclassified from accumulated OCI into income $ 7.6 $ 0.3 $ — $ — Location and Amount of Gain or (Loss) Recognized in Income on Cash Flow Hedging Relationships Three Months Ended March 31, 2018 Cost of sales Selling, general, and administrative expenses Total amounts of income and expense line items presented in the consolidated statements of operations in which the effects of fair value or cash flow hedges are recorded $ (233.6 ) $ (256.0 ) The effects of fair value and cash flow hedging: Gain (loss) on cash flow hedging relationships: Foreign currency contracts: Amount of gain (loss) reclassified from accumulated OCI into income $ (1.5 ) $ (1.1 ) |
STOCK-BASED COMPENSATION (Table
STOCK-BASED COMPENSATION (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Schedule of Stock-Based Compensation Expense | Stock-based compensation expense related to awards issued under the Company's incentive compensation plans for the three months ended March 31, 2019 and 2018 was as follows (in millions): Three Months Ended 2019 2018 Cost of sales $ 4.0 $ 3.0 Selling, general, and administrative expenses 12.7 11.8 Research and development expenses 4.1 3.6 Total stock-based compensation expense $ 20.8 $ 18.4 |
Schedule of Weighted-Average Assumptions for Options Granted | The following table includes the weighted-average grant-date fair values of stock options granted during the periods indicated and the related weighted-average assumptions used in the Black-Scholes option pricing model: Option Awards Three Months Ended 2019 2018 Average risk-free interest rate 2.5 % 2.6 % Expected dividend yield None None Expected volatility 29.2 % 33.2 % Expected term (years) 5.2 4.7 Fair value, per option $ 54.03 $ 43.45 |
Schedule of Weighted-Average Assumptions for ESPP Subscriptions Granted | The following table includes the weighted-average grant-date fair values for ESPP subscriptions granted during the periods indicated and the related weighted-average assumptions used in the Black-Scholes option pricing model: ESPP Three Months Ended 2019 2018 Average risk-free interest rate 2.4 % 1.5 % Expected dividend yield None None Expected volatility 32.6 % 32.6 % Expected term (years) 0.6 0.6 Fair value, per share $ 48.83 $ 35.07 |
ACCUMULATED OTHER COMPREHENSI_2
ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Equity [Abstract] | |
Summary of Activity for Each Component of Accumulated Other Comprehensive Loss | The following table is a summary of activity for each component of " Accumulated Other Comprehensive Loss " for the three months ended March 31, 2019 (in millions): Foreign Currency Translation Adjustments Unrealized Gain on Cash Flow Hedges Unrealized Loss on Available-for-sale Investments Unrealized Pension Costs Total Accumulated Other Comprehensive Loss December 31, 2018 $ (143.6 ) $ 23.6 $ (5.0 ) $ (13.5 ) $ (138.5 ) Other comprehensive (loss) gain before reclassifications (10.2 ) 15.6 4.4 (0.1 ) 9.7 Amounts reclassified from accumulated other comprehensive loss (1.6 ) (7.0 ) — — (8.6 ) Deferred income tax expense (1.3 ) (1.4 ) (1.1 ) — (3.8 ) March 31, 2019 $ (156.7 ) $ 30.8 $ (1.7 ) $ (13.6 ) $ (141.2 ) |
Schedule of Amounts Reclassified from Accumulated Other Comprehensive Loss | The following table provides information about amounts reclassified from " Accumulated Other Comprehensive Loss " (in millions): Three Months Ended Affected Line on Consolidated Condensed Statements of Operations Details about Accumulated Other Comprehensive Loss Components 2019 2018 Foreign currency translation adjustments $ 1.6 $ — Other income, net (0.4 ) — Provision for income taxes $ 1.2 $ — Net of tax Gain on hedges $ 7.6 $ (1.5 ) Cost of sales 0.3 (1.1 ) Selling, general, and administrative expenses (0.9 ) — Other income, net 7.0 (2.6 ) Total before tax (2.0 ) 0.7 Provision for income taxes $ 5.0 $ (1.9 ) Net of tax Loss on available-for-sale investments $ — $ (1.4 ) Other income, net — 0.1 Provision for income taxes $ — $ (1.3 ) Net of tax Unrealized pension costs $ — $ (0.6 ) Other income, net — 0.1 Provision for income taxes $ — $ (0.5 ) |
EARNINGS PER SHARE (Tables)
EARNINGS PER SHARE (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Earnings Per Share [Abstract] | |
Schedule of Computation of Basic and Diluted Earnings Per Share | The table below presents the computation of basic and diluted earnings per share (in millions, except for per share information): Three Months Ended 2019 2018 Basic: Net income $ 249.7 $ 206.6 Weighted-average shares outstanding 207.9 210.2 Basic earnings per share $ 1.20 $ 0.98 Diluted: Net income $ 249.7 $ 206.6 Weighted-average shares outstanding 207.9 210.2 Dilutive effect of stock plans 4.3 4.9 Dilutive weighted-average shares outstanding 212.2 215.1 Diluted earnings per share $ 1.18 $ 0.96 |
SEGMENT INFORMATION (Tables)
SEGMENT INFORMATION (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Segment Reporting [Abstract] | |
Information About Reportable Segments and Reconciliation of Segment Net Sales to Consolidated Net Sales and Segment Pre-Tax Income to Consolidated Pre-Tax Income | The table below presents information about Edwards Lifesciences' reportable segments (in millions): Three Months Ended 2019 2018 Segment Net Sales United States $ 562.8 $ 479.5 Europe 227.3 205.3 Japan 99.2 91.1 Rest of World 96.8 91.7 Total segment net sales $ 986.1 $ 867.6 Segment Operating Income United States $ 383.3 $ 313.8 Europe 119.4 103.0 Japan 61.0 54.8 Rest of World 30.8 29.0 Total segment operating income $ 594.5 $ 500.6 The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions): Three Months Ended 2019 2018 Net Sales Reconciliation Segment net sales $ 986.1 $ 867.6 Foreign currency 6.9 27.2 Consolidated net sales $ 993.0 $ 894.8 Pre-tax Income Reconciliation Segment operating income $ 594.5 $ 500.6 Unallocated amounts: Corporate items (306.5 ) (248.1 ) Special charge (Note 5) (24.0 ) — Intellectual property litigation expenses (4.6 ) (5.7 ) Foreign currency 14.8 5.7 Consolidated operating income 274.2 252.5 Non-operating income 3.8 11.0 Consolidated pre-tax income $ 278.0 $ 263.5 |
Enterprise-Wide Information | Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements. Three Months Ended 2019 2018 Net Sales by Geographic Area United States $ 562.8 $ 479.5 Europe 234.7 230.0 Japan 98.4 92.7 Rest of World 97.1 92.6 $ 993.0 $ 894.8 Net Sales by Major Product and Service Area Transcatheter Aortic Valve Replacement $ 597.7 $ 551.1 Transcatheter Mitral and Tricuspid Therapies 4.3 0.5 Surgical Structural Heart 214.7 179.5 Critical Care 176.3 163.7 $ 993.0 $ 894.8 March 31, 2019 December 31, 2018 (in millions) Long-lived Tangible Assets by Geographic Area United States $ 727.3 $ 642.1 Europe 51.4 36.6 Japan 16.7 6.7 Rest of World 242.1 214.4 $ 1,037.5 $ 899.8 |
BASIS OF PRESENTATION (Details)
BASIS OF PRESENTATION (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Jan. 01, 2019 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Operating lease right-of-use assets (Note 4) | $ 69.9 | |
Total lease liabilities | $ 72.3 | |
Accounting Standards Update 2016-02 | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Operating lease right-of-use assets (Note 4) | $ 58.7 | |
Total lease liabilities | $ 58.7 |
OTHER CONSOLIDATED FINANCIAL _3
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - Components of Selected Captions in the Consolidated Condensed Balance Sheets (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Inventories | ||
Raw materials | $ 112.3 | $ 111.5 |
Work in process | 161.2 | 144.8 |
Finished products | 357.4 | 350.7 |
Total inventories | 630.9 | 607 |
Finished products inventories held on consignment | $ 112.2 | $ 106.5 |
OTHER CONSOLIDATED FINANCIAL _4
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Accounts payable and accrued liabilities | ||
Accounts payable | $ 147.2 | $ 134 |
Employee compensation and withholdings | 152.7 | 226.1 |
Taxes payable (Note 14) | 6.9 | 31.3 |
Property, payroll, and other taxes | 42.2 | 39.5 |
Research and development accruals | 55.7 | 48.9 |
Accrued rebates | 72.4 | 80 |
Fair value of derivatives | 4 | 4.4 |
Accrued marketing expenses | 18.3 | 22.3 |
Litigation and insurance reserves | 18.6 | 196.7 |
Accrued relocation costs | 12.1 | 11.3 |
Accrued professional services | 7.5 | 11 |
Accrued technology purchases | 7.2 | 0 |
Other accrued liabilities | 79.1 | 71.1 |
Total accounts payable and accrued liabilities | $ 623.9 | $ 876.6 |
OTHER CONSOLIDATED FINANCIAL _5
OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - Supplemental Cash Flow Information (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Cash paid during the year for: | ||
Operating cash flows from operating leases | $ 6.1 | $ 0 |
Non-cash investing and financing transactions: | ||
Right-of-use assets obtained in exchange for new lease liabilities | 16.3 | 0 |
Capital expenditures accruals | $ 15.7 | $ 15.8 |
REVENUE (Details)
REVENUE (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Dec. 31, 2018 | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Deferred revenue | $ 7.9 | $ 7.6 |
Revenue recognized that was previously deferred | $ 1.1 | |
Hemodynamic Monitors | ||
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | ||
Contract length | The Company sells separately priced service contracts, which range from 12 months to 36 months, to owners of its hemodynamic monitors. |
LEASES - Narrative (Details)
LEASES - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |||
Mar. 31, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Lessee, Lease, Description [Line Items] | |||||
Operating lease cost | $ 6.3 | ||||
Operating leases expense | $ 27 | $ 27.3 | $ 22.9 | ||
Minimum | |||||
Lessee, Lease, Description [Line Items] | |||||
Lease term | 1 year | ||||
Lease not yet commenced term of contract | 1 year | ||||
Maximum | |||||
Lessee, Lease, Description [Line Items] | |||||
Lease term | 22 years | ||||
Lease not yet commenced term of contract | 10 years | ||||
Scenario, Forecast | |||||
Lessee, Lease, Description [Line Items] | |||||
Lease commitments for leases not yet commenced | $ 12.5 |
LEASES - Assets and Liabilities
LEASES - Assets and Liabilities of Operating Leases (Details) $ in Millions | Mar. 31, 2019USD ($) |
Leases [Abstract] | |
Operating lease right-of-use assets (Note 4) | $ 69.9 |
Operating lease liabilities, current portion | 22.6 |
Operating lease liabilities, long-term portion | 49.7 |
Total operating lease liabilities | $ 72.3 |
LEASES - Future Minimum Rental
LEASES - Future Minimum Rental Payments After Adoption of Topic 842 (Details) $ in Millions | Mar. 31, 2019USD ($) |
Leases [Abstract] | |
2019 | $ 18.8 |
2020 | 21.1 |
2021 | 13.9 |
2022 | 9.5 |
2023 | 6.9 |
Thereafter | 8.2 |
Total lease payments | 78.4 |
Imputed interest | (6.1) |
Total lease liabilities | $ 72.3 |
Weighted-average remaining lease term (in years) | 4 years 6 months |
Weighted-average discount rate | 3.00% |
LEASES - Future Minimum Renta_2
LEASES - Future Minimum Rental Payments Prior to Adopting Topic 842 (Details) $ in Millions | Dec. 31, 2018USD ($) |
Leases [Abstract] | |
2019 | $ 25.6 |
2020 | 21.5 |
2021 | 13.5 |
2022 | 9.9 |
2023 | 6.4 |
Thereafter | 14.3 |
Total obligations and commitments | $ 91.2 |
SPECIAL CHARGE (GAIN) Narrative
SPECIAL CHARGE (GAIN) Narrative (Details) - USD ($) $ in Millions | 1 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2019 | |
Pension Plan | ||
Restructuring Cost and Reserve [Line Items] | ||
Gain due to settlement | $ 7.1 | |
Early-stage Transcatheter Intellectual Property | ||
Restructuring Cost and Reserve [Line Items] | ||
Acquisition charges | $ 24 |
INVESTMENTS - Schedule of Inves
INVESTMENTS - Schedule of Investments in Debt Securities (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Held-to-maturity | ||
Cost | $ 30 | |
Fair Value | 30 | |
Available-for-sale | ||
Cost | 654.6 | $ 711.3 |
Gross Unrealized Gains | 1.5 | 0.4 |
Gross Unrealized Losses | (2.2) | (5.5) |
Fair Value | 653.9 | 706.2 |
Bank time deposits | ||
Held-to-maturity | ||
Cost | 30 | 20 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | 30 | 20 |
Commercial paper | ||
Available-for-sale | ||
Cost | 36 | 56.7 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | 36 | 56.7 |
U.S. government and agency securities | ||
Available-for-sale | ||
Cost | 79.7 | 79.7 |
Gross Unrealized Gains | 0.2 | 0.2 |
Gross Unrealized Losses | (0.4) | (0.7) |
Fair Value | 79.5 | 79.2 |
Foreign government bonds | ||
Available-for-sale | ||
Cost | 1.7 | 1.7 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | 1.7 | 1.7 |
Asset-backed securities | ||
Available-for-sale | ||
Cost | 102.2 | 110.6 |
Gross Unrealized Gains | 0.3 | 0.1 |
Gross Unrealized Losses | (0.3) | (0.5) |
Fair Value | 102.2 | 110.2 |
Corporate debt securities | ||
Available-for-sale | ||
Cost | 432.2 | 459.8 |
Gross Unrealized Gains | 1 | 0.1 |
Gross Unrealized Losses | (1.5) | (4.3) |
Fair Value | 431.7 | 455.6 |
Municipal securities | ||
Available-for-sale | ||
Cost | 2.8 | 2.8 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | $ 2.8 | $ 2.8 |
INVESTMENTS - Schedule of Cost
INVESTMENTS - Schedule of Cost and Fair Value of Investments in Debt Securities, By Contractual Maturity (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Cost | ||
Due in 1 year or less | $ 30 | |
Due after 1 year through 5 years | 0 | |
Instruments not due at a single maturity date | 0 | |
Cost | 30 | |
Fair Value | ||
Due in 1 year or less | 30 | |
Due after 1 year through 5 years | 0 | |
Instruments not due at a single maturity date | 0 | |
Fair Value | 30 | |
Cost | ||
Due in 1 year or less | 224.5 | |
Due after 1 year through 5 years | 340.9 | |
Instruments not due at a single maturity date | 89.2 | |
Cost | 654.6 | $ 711.3 |
Fair Value | ||
Due in 1 year or less | 223.8 | |
Due after 1 year through 5 years | 340.9 | |
Instruments not due at a single maturity date | 89.2 | |
Fair Value | $ 653.9 | $ 706.2 |
INVESTMENTS - Schedule of Inv_2
INVESTMENTS - Schedule of Investments in Continuous Loss Position (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Debt Securities, Available-for-sale [Line Items] | ||
Fair value, less than twelve months | $ 56.1 | $ 182.1 |
Gross unrealized losses, less than twelve months | (0.2) | (1.1) |
Fair value, twelve months or greater | 299.5 | 321.5 |
Gross unrealized losses, twelve months or greater | (2) | (4.4) |
Fair value, total | 355.6 | 503.6 |
Gross unrealized losses, total | (2.2) | (5.5) |
U.S. government and agency securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Fair value, less than twelve months | 0 | 0.7 |
Gross unrealized losses, less than twelve months | 0 | (0.1) |
Fair value, twelve months or greater | 56.7 | 56.5 |
Gross unrealized losses, twelve months or greater | (0.4) | (0.6) |
Fair value, total | 56.7 | 57.2 |
Gross unrealized losses, total | (0.4) | (0.7) |
Asset-backed securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Fair value, less than twelve months | 0 | 4 |
Gross unrealized losses, less than twelve months | 0 | 0.1 |
Fair value, twelve months or greater | 53.7 | 61.3 |
Gross unrealized losses, twelve months or greater | (0.3) | (0.6) |
Fair value, total | 53.7 | 65.3 |
Gross unrealized losses, total | (0.3) | (0.5) |
Corporate debt securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Fair value, less than twelve months | 56.1 | 177.4 |
Gross unrealized losses, less than twelve months | (0.2) | (1.1) |
Fair value, twelve months or greater | 189.1 | 203.7 |
Gross unrealized losses, twelve months or greater | (1.3) | (3.2) |
Fair value, total | 245.2 | 381.1 |
Gross unrealized losses, total | $ (1.5) | $ (4.3) |
INVESTMENTS - Schedule of Inv_3
INVESTMENTS - Schedule of Investments in Unconsolidated Affiliates (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Equity method investments | ||
Cost | $ 10.3 | $ 9.1 |
Equity in losses | (4.8) | (4.7) |
Carrying value of equity method investments | 5.5 | 4.4 |
Equity securities | ||
Carrying value of non-marketable equity securities | 18.1 | 18.1 |
Total investments in unconsolidated affiliates | $ 23.6 | $ 22.5 |
INVESTMENTS - Narrative (Detail
INVESTMENTS - Narrative (Details) - Other income, net $ in Millions | Mar. 31, 2019USD ($) |
Debt and Equity Securities, FV-NI [Line Items] | |
Increase in non-marketable equity securities due to observable price changes | $ 1.7 |
Decrease in non-marketable equity securities due to observable price changes | $ 1.9 |
ACQUISITION - Narrative (Detail
ACQUISITION - Narrative (Details) - CAS Medical Systems, Inc. $ / shares in Units, $ in Millions | Feb. 11, 2019USD ($)$ / shares |
Business Acquisition [Line Items] | |
Consideration per share to be transferred (in dollars per share) | $ / shares | $ 2.45 |
Acquisition price, subject to certain adjustments | $ | $ 100 |
FAIR VALUE MEASUREMENTS - Narra
FAIR VALUE MEASUREMENTS - Narrative (Details) $ in Millions | Mar. 31, 2019USD ($) |
Level 2 | |
Financial instruments | |
Notes payable fair value disclosure | $ 630.1 |
Discount Rate | Level 3 | Obligations | Minimum | |
Financial instruments | |
Contingent consideration liability measurement input | 0.024 |
Discount Rate | Level 3 | Obligations | Maximum | |
Financial instruments | |
Contingent consideration liability measurement input | 0.034 |
Probability of Milestone Achievement | Level 3 | Obligations | Minimum | |
Financial instruments | |
Contingent consideration liability measurement input | 0 |
Probability of Milestone Achievement | Level 3 | Obligations | Maximum | |
Financial instruments | |
Contingent consideration liability measurement input | 0.984 |
Volatility of Future Revenue | Level 3 | Obligations | |
Financial instruments | |
Contingent consideration liability measurement input | 0.450 |
FAIR VALUE MEASUREMENTS - Summa
FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Assets | ||
Available-for-sale investments | $ 653.9 | $ 706.2 |
Corporate debt securities | ||
Assets | ||
Available-for-sale investments | 431.7 | 455.6 |
Asset-backed securities | ||
Assets | ||
Available-for-sale investments | 102.2 | 110.2 |
U.S. government and agency securities | ||
Assets | ||
Available-for-sale investments | 79.5 | 79.2 |
Foreign government bonds | ||
Assets | ||
Available-for-sale investments | 1.7 | 1.7 |
Commercial paper | ||
Assets | ||
Available-for-sale investments | 36 | 56.7 |
Municipal securities | ||
Assets | ||
Available-for-sale investments | 2.8 | 2.8 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | ||
Assets | ||
Cash equivalents | 7 | 11.8 |
Investments held for deferred compensation plans | 76 | 67.6 |
Derivatives | 37.9 | 29.9 |
Assets | 774.8 | 815.5 |
Liabilities | ||
Derivatives | 4 | 5.2 |
Deferred compensation plans | 76.1 | 68.5 |
Contingent consideration liabilities | 185.3 | 178.6 |
Liabilities | 265.4 | 252.3 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Corporate debt securities | ||
Assets | ||
Available-for-sale investments | 431.7 | 455.6 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Asset-backed securities | ||
Assets | ||
Available-for-sale investments | 102.2 | 110.2 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | U.S. government and agency securities | ||
Assets | ||
Available-for-sale investments | 79.5 | 79.2 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Foreign government bonds | ||
Assets | ||
Available-for-sale investments | 1.7 | 1.7 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Commercial paper | ||
Assets | ||
Available-for-sale investments | 36 | 56.7 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Municipal securities | ||
Assets | ||
Available-for-sale investments | 2.8 | 2.8 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 1 | ||
Assets | ||
Cash equivalents | 7 | 0 |
Investments held for deferred compensation plans | 76 | 67.6 |
Derivatives | 0 | 0 |
Assets | 102.7 | 87.2 |
Liabilities | ||
Derivatives | 0 | 0 |
Deferred compensation plans | 76.1 | 68.5 |
Contingent consideration liabilities | 0 | |
Liabilities | 76.1 | 68.5 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 1 | Corporate debt securities | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 1 | Asset-backed securities | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 1 | U.S. government and agency securities | ||
Assets | ||
Available-for-sale investments | 19.7 | 19.6 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 1 | Foreign government bonds | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 1 | Commercial paper | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 1 | Municipal securities | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 2 | ||
Assets | ||
Cash equivalents | 0 | 11.8 |
Investments held for deferred compensation plans | 0 | 0 |
Derivatives | 37.9 | 29.9 |
Assets | 672.1 | 728.3 |
Liabilities | ||
Derivatives | 4 | 5.2 |
Deferred compensation plans | 0 | 0 |
Contingent consideration liabilities | 0 | 0 |
Liabilities | 4 | 5.2 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 2 | Corporate debt securities | ||
Assets | ||
Available-for-sale investments | 431.7 | 455.6 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 2 | Asset-backed securities | ||
Assets | ||
Available-for-sale investments | 102.2 | 110.2 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 2 | U.S. government and agency securities | ||
Assets | ||
Available-for-sale investments | 59.8 | 59.6 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 2 | Foreign government bonds | ||
Assets | ||
Available-for-sale investments | 1.7 | 1.7 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 2 | Commercial paper | ||
Assets | ||
Available-for-sale investments | 36 | 56.7 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 2 | Municipal securities | ||
Assets | ||
Available-for-sale investments | 2.8 | 2.8 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 3 | ||
Assets | ||
Cash equivalents | 0 | 0 |
Investments held for deferred compensation plans | 0 | 0 |
Derivatives | 0 | 0 |
Assets | 0 | 0 |
Liabilities | ||
Derivatives | 0 | 0 |
Deferred compensation plans | 0 | 0 |
Contingent consideration liabilities | 185.3 | 178.6 |
Liabilities | 185.3 | 178.6 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 3 | Corporate debt securities | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 3 | Asset-backed securities | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 3 | U.S. government and agency securities | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 3 | Foreign government bonds | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 3 | Commercial paper | ||
Assets | ||
Available-for-sale investments | 0 | 0 |
Estimate of Fair Value Measurement | Fair Value on a Recurring Basis | Level 3 | Municipal securities | ||
Assets | ||
Available-for-sale investments | $ 0 | $ 0 |
FAIR VALUE MEASUREMENTS - Sum_2
FAIR VALUE MEASUREMENTS - Summary of Changes in Fair Value of Contingent Consideration Obligation (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation | |
Beginning balance | $ 178.6 |
Changes in fair value | 6.7 |
Ending balance | $ 185.3 |
DERIVATIVE INSTRUMENTS AND HE_3
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Summary of Derivative Financial Instruments Used to Manage Currency Exchange Rate Risk and Interest Rate Risk (Details) - Derivatives designated as hedging instruments - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Foreign currency forward exchange contracts | ||
Derivative Financial Instruments | ||
Notional Amount | $ 1,326.1 | $ 1,378.2 |
Cross currency swap contracts | ||
Derivative Financial Instruments | ||
Notional Amount | $ 300 | $ 300 |
DERIVATIVE INSTRUMENTS AND HE_4
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) € in Millions, $ in Millions | 3 Months Ended | |||
Mar. 31, 2019USD ($) | Mar. 31, 2019EUR (€) | Dec. 31, 2018USD ($) | Jun. 30, 2018EUR (€) | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||||
Changes due to currency rate movements and expenses expected to occur, maximum term | 13 months | |||
Derivative Financial Instruments | ||||
Gain expected to be reclassified as earnings | $ 12.3 | |||
Derivatives designated as hedging instruments | Cross currency swap contracts | ||||
Derivative Financial Instruments | ||||
Derivative liability, fair value | 300 | $ 300 | ||
Net investment hedges | Derivatives designated as hedging instruments | Foreign currency denominated debt | ||||
Derivative Financial Instruments | ||||
Derivative liability, fair value | € | € 370 | |||
Net investment hedges | Derivatives designated as hedging instruments | Cross currency swap contracts | ||||
Derivative Financial Instruments | ||||
Derivative liability, fair value | $ 300 | € 257.2 |
DERIVATIVE INSTRUMENTS AND HE_5
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Location and Fair Value Amounts of Derivative Instruments Reported in Consolidated Condensed Balance Sheets (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Foreign currency contracts | ||
Assets | ||
Fair value of derivative assets | $ 31.8 | $ 29.1 |
Liabilities | ||
Fair value of derivative liabilities | 4 | 5.2 |
Cross currency swap contracts | ||
Assets | ||
Fair value of derivative assets | 6.1 | 0.8 |
Derivatives designated as hedging instruments | Foreign currency contracts | Other current assets | ||
Assets | ||
Fair value of derivative assets | 30.2 | 29.1 |
Derivatives designated as hedging instruments | Foreign currency contracts | Other assets | ||
Assets | ||
Fair value of derivative assets | 1.6 | 0 |
Derivatives designated as hedging instruments | Foreign currency contracts | Accounts payable and accrued liabilities | ||
Liabilities | ||
Fair value of derivative liabilities | 4 | 4.4 |
Derivatives designated as hedging instruments | Foreign currency contracts | Other long-term liabilities | ||
Liabilities | ||
Fair value of derivative liabilities | 0 | 0.8 |
Derivatives designated as hedging instruments | Cross currency swap contracts | Other assets | ||
Assets | ||
Fair value of derivative assets | $ 6.1 | $ 0.8 |
DERIVATIVE INSTRUMENTS AND HE_6
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Effect of Master-Netting Agreements and Rights of Offset, Derivative Assets and Liabilities (Details) - USD ($) $ in Millions | Mar. 31, 2019 | Dec. 31, 2018 |
Foreign currency contracts | ||
Derivative assets | ||
Gross Amounts | $ 31.8 | $ 29.1 |
Gross Amounts Offset in the Consolidated Balance Sheet | 0 | 0 |
Net Amounts Presented in the Consolidated Balance Sheet | 31.8 | 29.1 |
Gross Amounts Not Offset in the Consolidated Balance Sheet | ||
Financial Instruments | (4) | (3.6) |
Cash Collateral Received | 0 | 0 |
Net Amount | 27.8 | 25.5 |
Derivative liabilities | ||
Gross Amounts | 4 | 5.2 |
Gross Amounts Offset in the Consolidated Balance Sheet | 0 | 0 |
Net Amounts Presented in the Consolidated Balance Sheet | 4 | 5.2 |
Gross Amounts Not Offset in the Consolidated Balance Sheet | ||
Financial Instruments | (4) | (3.6) |
Cash Collateral Received | 0 | 0 |
Net Amount | 0 | 1.6 |
Cross currency swap contracts | ||
Derivative assets | ||
Gross Amounts | 6.1 | 0.8 |
Gross Amounts Offset in the Consolidated Balance Sheet | 0 | 0 |
Net Amounts Presented in the Consolidated Balance Sheet | 6.1 | 0.8 |
Gross Amounts Not Offset in the Consolidated Balance Sheet | ||
Financial Instruments | 0 | 0 |
Cash Collateral Received | 0 | 0 |
Net Amount | $ 6.1 | $ 0.8 |
DERIVATIVE INSTRUMENTS AND HE_7
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Effect of Derivative Instruments on Consolidated Condensed Statements of Operations and Consolidated Condensed Statements of Comprehensive Income (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Foreign currency contracts | Derivatives not designated as hedging instruments | Other income, net | ||
Derivative Instruments, Gain (Loss) | ||
Amount of Gain or (Loss) Recognized in Income on Derivative | $ (1.5) | $ (8.9) |
Cash flow hedges | Foreign currency contracts | Derivatives designated as hedging instruments | ||
Derivative Instruments, Gain (Loss) | ||
Amount of Gain or (Loss) Recognized in OCI on Derivative | 12.9 | (15.4) |
Cash flow hedges | Foreign currency contracts | Derivatives designated as hedging instruments | Cost of sales | ||
Derivative Instruments, Gain (Loss) | ||
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income | 7.6 | (1.5) |
Cash flow hedges | Foreign currency contracts | Derivatives designated as hedging instruments | Selling, general, and administrative expenses | ||
Derivative Instruments, Gain (Loss) | ||
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income | 0.3 | (1.1) |
Net investment hedges | Cross currency swap contracts | Derivatives designated as hedging instruments | ||
Derivative Instruments, Gain (Loss) | ||
Amount of Gain or (Loss) Recognized in OCI on Derivative | 5.3 | 0 |
Net investment hedges | Cross currency swap contracts | Derivatives designated as hedging instruments | Interest expense (income), net | ||
Derivative Instruments, Gain (Loss) | ||
Amount of Gain or (Loss) Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) | 1.6 | 0 |
Net investment hedges | Foreign currency denominated debt | Derivatives designated as hedging instruments | ||
Derivative Instruments, Gain (Loss) | ||
Amount of Gain or (Loss) Recognized in OCI on Derivative | 0 | (20.2) |
Fair value hedges | Foreign currency contracts | Derivatives designated as hedging instruments | Other income, net | ||
Derivative Instruments, Gain (Loss) | ||
Amount of Gain or (Loss) Recognized in Income on Derivative | $ (0.9) | $ 0 |
DERIVATIVE INSTRUMENTS AND HE_8
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Cash Flow Hedge Effects on Statement of Operations (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Derivative Instruments, Gain (Loss) | ||
Cost of sales | $ (231.8) | $ (233.6) |
Selling, general, and administrative expenses | (280.3) | (256) |
Interest expense (income), net | 2 | 0.8 |
Other income, net | (1.8) | (3.1) |
Foreign currency contracts | Cost of sales | ||
Gain (loss) on fair value hedging relationships: | ||
Hedged items | 0 | |
Amount excluded from effectiveness testing recognized in earnings based on an amortization approach | 0 | |
Gain (loss) on cash flow hedging relationships: | ||
Amount of gain (loss) reclassified from accumulated OCI into income | 7.6 | (1.5) |
Foreign currency contracts | Cost of sales | Derivatives designated as hedging instruments | ||
Gain (loss) on fair value hedging relationships: | ||
Derivatives designated as hedging instruments | 0 | |
Foreign currency contracts | Selling, general, and administrative expenses | ||
Gain (loss) on fair value hedging relationships: | ||
Hedged items | 0 | |
Amount excluded from effectiveness testing recognized in earnings based on an amortization approach | 0 | |
Gain (loss) on cash flow hedging relationships: | ||
Amount of gain (loss) reclassified from accumulated OCI into income | 0.3 | $ (1.1) |
Foreign currency contracts | Selling, general, and administrative expenses | Derivatives designated as hedging instruments | ||
Gain (loss) on fair value hedging relationships: | ||
Derivatives designated as hedging instruments | 0 | |
Foreign currency contracts | Interest expense (income), net | ||
Gain (loss) on fair value hedging relationships: | ||
Hedged items | 0 | |
Amount excluded from effectiveness testing recognized in earnings based on an amortization approach | 0 | |
Gain (loss) on cash flow hedging relationships: | ||
Amount of gain (loss) reclassified from accumulated OCI into income | 0 | |
Foreign currency contracts | Interest expense (income), net | Derivatives designated as hedging instruments | ||
Gain (loss) on fair value hedging relationships: | ||
Derivatives designated as hedging instruments | 0 | |
Foreign currency contracts | Other Expense, net | ||
Gain (loss) on fair value hedging relationships: | ||
Hedged items | 1.8 | |
Amount excluded from effectiveness testing recognized in earnings based on an amortization approach | 0.9 | |
Gain (loss) on cash flow hedging relationships: | ||
Amount of gain (loss) reclassified from accumulated OCI into income | 0 | |
Foreign currency contracts | Other Expense, net | Derivatives designated as hedging instruments | ||
Gain (loss) on fair value hedging relationships: | ||
Derivatives designated as hedging instruments | $ (1.8) |
STOCK-BASED COMPENSATION - Sche
STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Allocation of stock-based compensation expense | ||
Total stock-based compensation expense | $ 20.8 | $ 18.4 |
Cost of sales | ||
Allocation of stock-based compensation expense | ||
Total stock-based compensation expense | 4 | 3 |
Selling, general, and administrative expenses | ||
Allocation of stock-based compensation expense | ||
Total stock-based compensation expense | 4.1 | 3.6 |
Research and development expenses | ||
Allocation of stock-based compensation expense | ||
Total stock-based compensation expense | $ 12.7 | $ 11.8 |
STOCK-BASED COMPENSATION - Narr
STOCK-BASED COMPENSATION - Narrative (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2019USD ($) | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Total remaining unrecognized compensation cost | $ 110.4 |
Unrecognized compensation cost, recognition period | 29 months |
STOCK-BASED COMPENSATION - Sc_2
STOCK-BASED COMPENSATION - Schedule of Weighted-Average Assumptions for Options and ESPP Subscriptions Granted Granted (Details) - $ / shares | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Option Awards | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Average risk-free interest rate | 2.50% | 2.60% |
Expected dividend yield | 0.00% | 0.00% |
Expected volatility (as a percent) | 29.00% | 33.00% |
Expected term | 5 years 2 months 12 days | 4 years 8 months 12 days |
Fair value, per option (in dollars per share) | $ 54.03 | $ 43.45 |
ESPP | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Average risk-free interest rate | 2.40% | 1.50% |
Expected dividend yield | 0.00% | 0.00% |
Expected volatility (as a percent) | 33.00% | 33.00% |
Expected term | 7 months 6 days | 7 months 6 days |
Fair value, per option (in dollars per share) | $ 48.83 | $ 35.07 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Details) | 3 Months Ended |
Mar. 31, 2019lawsuit | |
Commitments and Contingencies Disclosure [Abstract] | |
Number of lawsuits that if settled could have a material adverse impact on net income or cash flows | 1 |
ACCUMULATED OTHER COMPREHENSI_3
ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Activity for Each Component of Accumulated Other Comprehensive Loss (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2019USD ($) | |
AOCI Attributable to Parent, Net of Tax | |
Beginning balance | $ 3,140.4 |
Other comprehensive (loss) gain before reclassifications | 9.7 |
Amounts reclassified from accumulated other comprehensive loss | (8.6) |
Deferred income tax expense | (3.8) |
Ending balance | 3,447.5 |
Foreign Currency Translation Adjustments | |
AOCI Attributable to Parent, Net of Tax | |
Beginning balance | (143.6) |
Other comprehensive (loss) gain before reclassifications | (10.2) |
Amounts reclassified from accumulated other comprehensive loss | (1.6) |
Deferred income tax expense | (1.3) |
Ending balance | (156.7) |
Unrealized Gain on Cash Flow Hedges | |
AOCI Attributable to Parent, Net of Tax | |
Beginning balance | 23.6 |
Other comprehensive (loss) gain before reclassifications | 15.6 |
Amounts reclassified from accumulated other comprehensive loss | (7) |
Deferred income tax expense | (1.4) |
Ending balance | 30.8 |
Unrealized Loss on Available-for-sale Investments | |
AOCI Attributable to Parent, Net of Tax | |
Beginning balance | (5) |
Other comprehensive (loss) gain before reclassifications | 4.4 |
Amounts reclassified from accumulated other comprehensive loss | 0 |
Deferred income tax expense | (1.1) |
Ending balance | (1.7) |
Unrealized Pension Costs | |
AOCI Attributable to Parent, Net of Tax | |
Beginning balance | (13.5) |
Other comprehensive (loss) gain before reclassifications | (0.1) |
Amounts reclassified from accumulated other comprehensive loss | 0 |
Deferred income tax expense | 0 |
Ending balance | (13.6) |
Total Accumulated Other Comprehensive Loss | |
AOCI Attributable to Parent, Net of Tax | |
Beginning balance | (138.5) |
Ending balance | $ (141.2) |
ACCUMULATED OTHER COMPREHENSI_4
ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Amounts Reclassified from Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Affected Line on Consolidated Condensed Statements of Operations | ||
Cost of sales | $ (231.8) | $ (233.6) |
Selling, general, and administrative expenses | (280.3) | (256) |
Income before provision for income taxes | 278 | 263.5 |
Provision for income taxes | (28.3) | (56.9) |
Other income, net | 1.8 | 3.1 |
Net income | 249.7 | 206.6 |
Amount Reclassified from Accumulated Other Comprehensive Loss | Foreign Currency Translation Adjustments | ||
Affected Line on Consolidated Condensed Statements of Operations | ||
Provision for income taxes | (0.4) | 0 |
Other income, net | 1.6 | 0 |
Net income | 1.2 | 0 |
Amount Reclassified from Accumulated Other Comprehensive Loss | Unrealized Gain on Cash Flow Hedges | ||
Affected Line on Consolidated Condensed Statements of Operations | ||
Cost of sales | 7.6 | (1.5) |
Selling, general, and administrative expenses | 0.3 | (1.1) |
Other income, net | (0.9) | 0 |
Income before provision for income taxes | 7 | (2.6) |
Provision for income taxes | (2) | 0.7 |
Net income | 5 | (1.9) |
Amount Reclassified from Accumulated Other Comprehensive Loss | Loss on available-for-sale investments | ||
Affected Line on Consolidated Condensed Statements of Operations | ||
Provision for income taxes | 0 | 0.1 |
Other income, net | 0 | (1.4) |
Net income | 0 | (1.3) |
Amount Reclassified from Accumulated Other Comprehensive Loss | Unrealized Pension Costs | ||
Affected Line on Consolidated Condensed Statements of Operations | ||
Provision for income taxes | 0 | 0.1 |
Other income, net | 0 | (0.6) |
Net income | $ 0 | $ (0.5) |
EARNINGS PER SHARE - Schedule o
EARNINGS PER SHARE - Schedule of Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Basic: | ||
Net income | $ 249.7 | $ 206.6 |
Weighted-average shares outstanding (in shares) | 207.9 | 210.2 |
Basic earnings per share (in dollars per share) | $ 1.20 | $ 0.98 |
Diluted: | ||
Net income | $ 249.7 | $ 206.6 |
Weighted-average shares outstanding (in shares) | 207.9 | 210.2 |
Dilutive effect of stock plans (in shares) | 4.3 | 4.9 |
Dilutive weighted-average shares outstanding (in shares) | 212.2 | 215.1 |
Diluted earnings per share (in dollars per share) | $ 1.18 | $ 0.96 |
EARNINGS PER SHARE - Narrative
EARNINGS PER SHARE - Narrative (Details) - shares shares in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Stock compensation plan | ||
Anti-dilutive securities | ||
Anti-dilutive securities excluded from the computation of earnings per share (in shares) | 0.2 | 1.2 |
INCOME TAXES (Details)
INCOME TAXES (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | |
Income Tax Disclosure [Abstract] | |||
Effective income tax rate | 10.20% | 21.60% | |
Adjustment to tax form related restructuring expense | $ 24 | ||
Tax benefit from employee share-based compensation | 19 | $ 14.2 | |
Liability for income taxes associated with uncertain tax positions | 161.9 | $ 150.7 | |
Decrease in unrecognized tax benefits is reasonably possible | 47.4 | 42.7 | |
Net amounts that would favorably affect effective tax rate | $ 114.5 | $ 108 |
SEGMENT INFORMATION - Informati
SEGMENT INFORMATION - Information About Reportable Segments (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Segment Net Sales | ||
Net sales | $ 993 | $ 894.8 |
Segment Operating Income | ||
Consolidated pre-tax income | 278 | 263.5 |
Operating segments | ||
Segment Net Sales | ||
Net sales | 986.1 | 867.6 |
Segment Operating Income | ||
Consolidated pre-tax income | 594.5 | 500.6 |
Operating segments | United States | ||
Segment Net Sales | ||
Net sales | 562.8 | 479.5 |
Segment Operating Income | ||
Consolidated pre-tax income | 383.3 | 313.8 |
Operating segments | Europe | ||
Segment Net Sales | ||
Net sales | 227.3 | 205.3 |
Segment Operating Income | ||
Consolidated pre-tax income | 119.4 | 103 |
Operating segments | Japan | ||
Segment Net Sales | ||
Net sales | 99.2 | 91.1 |
Segment Operating Income | ||
Consolidated pre-tax income | 61 | 54.8 |
Operating segments | Rest of World | ||
Segment Net Sales | ||
Net sales | 96.8 | 91.7 |
Segment Operating Income | ||
Consolidated pre-tax income | $ 30.8 | $ 29 |
SEGMENT INFORMATION - Reconcili
SEGMENT INFORMATION - Reconciliations of Segment Net Sales to Consolidated Net Sales and Segment Pre-Tax Income to Consolidated Pre-Tax Income (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
Net Sales Reconciliation | ||
Net sales | $ 993 | $ 894.8 |
Pre-tax Income Reconciliation | ||
Operating income | 274.2 | 252.5 |
Unallocated amounts: | ||
Special charge (Note 5) | (24) | 0 |
Consolidated pre-tax income | 278 | 263.5 |
Operating segments | ||
Net Sales Reconciliation | ||
Net sales | 986.1 | 867.6 |
Pre-tax Income Reconciliation | ||
Operating income | 594.5 | 500.6 |
Unallocated amounts: | ||
Consolidated pre-tax income | 594.5 | 500.6 |
Reconciling items | ||
Net Sales Reconciliation | ||
Net sales | 6.9 | 27.2 |
Unallocated amounts: | ||
Intellectual property litigation expenses | (4.6) | (5.7) |
Foreign currency | 14.8 | 5.7 |
Non-operating income | 3.8 | 11 |
Corporate items | ||
Unallocated amounts: | ||
Corporate items | $ (306.5) | $ (248.1) |
SEGMENT INFORMATION - Enterpris
SEGMENT INFORMATION - Enterprise-Wide Information (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | |
Enterprise-Wide Information | |||
Net sales | $ 993 | $ 894.8 | |
Long-lived Tangible Assets by Geographic Area | |||
Long-lived tangible assets | 1,037.5 | $ 899.8 | |
Transcatheter Aortic Valve Replacement | |||
Enterprise-Wide Information | |||
Net sales | 597.7 | 551.1 | |
Transcatheter Mitral and Tricuspid Therapies | |||
Enterprise-Wide Information | |||
Net sales | 4.3 | 0.5 | |
Surgical Structural Heart | |||
Enterprise-Wide Information | |||
Net sales | 214.7 | 179.5 | |
Critical Care | |||
Enterprise-Wide Information | |||
Net sales | 176.3 | 163.7 | |
United States | |||
Enterprise-Wide Information | |||
Net sales | 562.8 | 479.5 | |
Long-lived Tangible Assets by Geographic Area | |||
Long-lived tangible assets | 727.3 | 642.1 | |
Europe | |||
Enterprise-Wide Information | |||
Net sales | 234.7 | 230 | |
Long-lived Tangible Assets by Geographic Area | |||
Long-lived tangible assets | 51.4 | 36.6 | |
Japan | |||
Enterprise-Wide Information | |||
Net sales | 98.4 | 92.7 | |
Long-lived Tangible Assets by Geographic Area | |||
Long-lived tangible assets | 16.7 | 6.7 | |
Rest of World | |||
Enterprise-Wide Information | |||
Net sales | 97.1 | $ 92.6 | |
Long-lived Tangible Assets by Geographic Area | |||
Long-lived tangible assets | $ 242.1 | $ 214.4 |
Uncategorized Items - ew-201903
Label | Element | Value |
Cumulative Effect of New Accounting Principle in Period of Adoption | us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption | $ 2,600,000 |
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance | us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 | 2,958,800,000 |
Treasury Stock [Member] | ||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance | us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 | (252,100,000) |
Retained Earnings [Member] | ||
Cumulative Effect of New Accounting Principle in Period of Adoption | us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption | 10,400,000 |
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance | us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 | 1,972,500,000 |
AOCI Attributable to Parent [Member] | ||
Cumulative Effect of New Accounting Principle in Period of Adoption | us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption | (7,800,000) |
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance | us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 | (140,500,000) |
Common Stock [Member] | ||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance | us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 | 212,000,000 |
Additional Paid-in Capital [Member] | ||
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance | us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 | $ 1,166,900,000 |